Furthermore, O
the O
levels O
of O
the O
CYP4F2 O
protein O
and O
of O
FA B-lipid
20:4;O I-lipid
were O
higher O
in O
ovarian O
cancer O
samples O
compared O
to O
normal O
control O
tissues. O

In O
a O
mass O
spectrometry-based O
study, O
plasma O
LPC B-lipid
16:0 I-lipid
was O
more O
significantly O
decreased O
in O
lung O
cancer O
patients O
than O
in O
healthy O
controls. O

An O
amount O
of O
50 μL O
of O
the O
internal O
standard O
solution O
(containing O
0.54 nmol O
TG B-lipid
57:0, I-lipid
0.59 nmol O
TG B-lipid
51:0, I-lipid
and O
0.73 nmol O
DG B-lipid
40:0) I-lipid
was O
added O
to O
a O
sample O
volume O
of O
100 μL O
(2 mg O
dw/mL) O
fecal O
homogenate O
prior O
to O
lipid O
extraction O
and O
extracted O
according O
to O
the O
protocol O
of O
Bligh O
and O
Dyer O
with O
a O
total O
chloroform O
volume O
of O
2 mL O
and O
an O
extraction O
time O
of O
60 min O
at O
room O
temperature. O

PC B-lipid
28:1, I-lipid
PC B-lipid
30:2 I-lipid
and O
PC B-lipid
38:0 I-lipid
for O
which O
CLR O
estimated O
considerably O
lower O
most-probable O
concentrations O
than O
Biocrates; O
2). O

(A) O
Scores O
plot O
from O
OPLS O
multivariate O
analysis, O
cross-validated O
score O
plot O
resulting O
from O
OPLS O
modeling O
of O
Total O
Blood O
ST B-lipid
27:1;O. I-lipid

On O
the O
contrary, O
the O
abundances O
of O
LPC B-lipid
17:1, I-lipid
LPC B-lipid
16:1, I-lipid
PC B-lipid
32:1 I-lipid
and O
PE O
(p-36:4) O
were O
lower O
in O
the O
meloxicam O
group O
after O
the O
administration O
of O
the O
drug O
 relative O
to O
baseline. O

By O
UPLC-MS, O
PE B-lipid
36:2 I-lipid
and O
PC B-lipid
O-36:5 I-lipid
were O
higher O
in O
PRP O
compared O
with O
PFP O
samples. O

For O
example, O
recovery O
of O
PC B-lipid
34:1 I-lipid
(p<0.001) O
increased O
by O
40%, O
and O
PE B-lipid
38:4 I-lipid
(p=0.012) O
increased O
by O
58%. O

High O
concentrations O
of O
PGs, O
FA B-lipid
20:4;O2 I-lipid
and O
cysteinyl-leukotrienes O
have O
been O
reported O
to O
promote O
the O
accumulation O
of O
inflammatory O
cells O
such O
as O
polymorphonuclear O
leukocytes O
(PMNs) O
by O
increasing O
the O
blood O
flow O
and O
vascular O
permeability O
. O

All O
of O
the O
11 O
metabolites O
except O
4 O
(3-hydroxybutyrate, O
N-acetyl-glycine, O
FA B-lipid
5:0;O I-lipid
and O
nonanedioic O
acid) O
have O
been O
identified O
as O
breast O
cancer O
associated O
in O
previous O
studies O
(-). O

The O
largest O
lipid O
% O
decrease O
was O
that O
of O
TG B-lipid
48:1 I-lipid
(CHEBI: O
85726), O
with O
a O
median O
decrease O
of O
43.1%. O

Additionally, O
in O
the O
CTS O
analysis O
of O
PS B-lipid
37:4 I-lipid
a O
product O
ion O
at O
m/z O
709, O
which O
corresponded O
to O
the O
neutral O
loss O
of O
serine O
(87 O
Da), O
was O
observed O
and O
the O
resultant O
product O
ion O
had O
the O
same O
structure O
as O
the O
molecular O
ion O
of O
PA O
and O
therefore O
same O
CCS O
of O
271 O
Å_2 O
. O

FA B-lipid
16:0 I-lipid
(C16:0) O
is O
reported O
to O
induce O
lipoapoptosis O
in O
hepatocytes O
via O
mechanisms, O
including O
mitochondrial O
dysfunction O
and O
stress O
of O
endoplasmic O
reticulum. O

, O
Our O
data O
clearly O
suggest O
that O
PC B-lipid
34:1 I-lipid
may O
contain O
four O
structural O
isomers O
from O
combinations O
of O
two O
sn O
-isomers O
and O
two O
CC O
location O
isomers O
of O
the O
C18:1. O

The O
urinary O
excretion O
of O
FA B-lipid
20:4;O I-lipid
was O
significantly O
lower O
in O
subjects O
with O
renovascular O
disease O
(median: O
12.9 O
μ O
g/g O
of O
creatinine; O
range: O
4.4 O
to O
24.9 O
μ O
g/g O
of O
creatinine) O
than O
in O
control O
subjects O
(median: O
31.0 O
μ O
g/g O
of O
creatinine; O
range: O
11.9 O
to O
102.8 O
μ O
g/g O
of O
creatinine; O
P O
<0.01) O
and O
essential O
hypertensive O
subjects O
(median: O
35.9 O
μ O
g/g O
of O
creatinine; O
range: O
14.0 O
to O
72.5 O
μ O
g/g O
of O
creatinine; O
P O
<0.05). O

 b) O
and O
the O
alkenyl-acyl O
form O
PC32p:0 O
by O
the O
presence O
of O
the O
FA B-lipid
16:0 I-lipid
(m/z O
255.2327) O
at O
9.3 min O
(Fig. O

There O
were O
six O
main O
findings O
of O
this O
study O
in O
relation O
to O
HCC O
versus O
controls, O
(1) O
that O
two O
bile O
acid O
conjugates O
and O
two O
fetal O
bile O
acids O
were O
elevated, O
(2) O
that O
bilirubin O
and O
biliverdin O
were O
elevated, O
(3) O
that O
11 O
lysophospholipids O
were O
attenuated, O
(4) O
that O
two O
very O
long-chain O
fatty O
acids O
were O
attenuated, O
(5) O
that O
LPA B-lipid
16:0 I-lipid
was O
considerably O
elevated O
in O
4/20 O
HCC O
patients, O
and O
(6) O
that O
in O
the O
HCC O
group O
as O
a O
whole O
LPA O
16:0 O
was O
strongly O
correlated O
with O
plasma O
AFP O
concentration. O

The O
ABCD2 O
+ O
LAA O
+ O
LPC B-lipid
20:4 I-lipid
model O
showed O
the O
highest O
calibration O
(χ_2 O
3.58, O
p O
= O
0.309), O
whereas O
the O
ABCD2 O
+ O
LAA O
+ O
LPC B-lipid
16:0 I-lipid
model O
showed O
the O
lowest O
calibration O
values O
(χ_2 O
17.33, O
p O

Kaplan-Meier O
survival O
curves O
and O
log-rank O
tests O
were O
performed, O
and O
the O
P O
values O
were O
0.0011, O
0.0012, O
0.0050, O
<0.0001 O
for O
Kynurenine, O
Acetylcarnitine, O
PC B-lipid
42:11, I-lipid
LPE B-lipid
22:0, I-lipid
respectively O
(Figure O
) O
and O
suggested O
poor O
survival O
with O
the O
increase O
of O
Kynurenine, O
Acetylcarnitine O
and O
PC O
42:11 O
and O
with O
the O
decrease O
of O
LPE O
22:0. O

, O
A O
higher O
amount O
of O
PE B-lipid
38:4 I-lipid
(p=0.094) O
was O
extracted O
with O
the O
methanol-ethanol O
precipitation O
compared O
to O
methanol O
only O
precipitation. O

FA B-lipid
20:4;O I-lipid
and O
leukotriene O
B_4 O
are O
metabolites O
associated O
with O
arachidonic O
acid O
(C20:4) O
metabolism. O

iPF_2a O
IV (P O
 = 0.021), O
FA B-lipid
20:4;O I-lipid
(P O
 = 0.040), O
FA O
20:4;O O
(P O
 = 0.019), O
FA B-lipid
20:3;O2 I-lipid
(P O
 = 0.017) O
and O
FA B-lipid
22:6;O I-lipid
(P O
 = 0.033). O

Only O
one O
PC O
in O
our O
study O
significantly O
increased O
in O
fatalities, O
PC B-lipid
32:0. I-lipid

Thus, O
compared O
to O
young O
men, O
young O
women O
had O
approximately O
3–4 O
fold O
higher O
content O
of O
three O
PUFAs O
including O
AA, O
FA B-lipid
22:5 I-lipid
(DPA), O
and O
FA B-lipid
20:5 I-lipid
(EPA). O

The O
metabolites O
FA B-lipid
20:5;O I-lipid
and O
FA O
20:5;O O
are O
produced O
via O
the O
LOX O
pathway, O
but O
with O
EPA O
as O
precursor O
fatty O
acid. O

Non-esterified O
diols O
and O
alcohols O
of O
C18-PUFA O
LA O
and O
ALA O
in O
cluster O
1, O
represented O
by O
FA B-lipid
18:2;O, I-lipid
were O
enriched O
to O
a O
greater O
extent O
postprandially O
in O
pro-atherogenic O
TGRL. O

Compared O
to O
elderly O
levels O
of O
FA B-lipid
20:5 I-lipid
(EPA) O
decreased O
also O
in O
centenarians. O

In O
this O
study, O
the O
LacCer B-lipid
34:1;O2 I-lipid
level O
was O
highest O
in O
the O
BT O
group, O
followed O
by O
GP O
and O
being O
lowest O
in O
PP. O

Valine, O
leucine, O
bilirubin, O
1‐methylnicotinamide, O
and O
seven O
LysoPCs O
(LPC O
15:0, I-lipid
LysoPC O
(16:0), O
LysoPC(16:0) O
isomer, O
LysoPC(P‐16:0), O
LPC B-lipid
16:1, I-lipid
LPC B-lipid
17:0, I-lipid
LPC B-lipid
18:0) I-lipid
showed O
higher O
relative O
mean O
intensity O
values O
in O
the O
control O
group O
compared O
to O
the O
colorectal O
cancer O
patient O
group, O
indicating O
an O
OR.std O
lower O
than O
one O
(Table O
). O

Serum O
alanine O
aminotransferase O
(ALT), O
aspartate O
aminotransferase O
(AST), O
gamma-glutamyl O
transferase O
(GT), O
glucose, O
cholesterol, O
and O
triglyceride O
concentrations O
were O
measured O
with O
ALT, O
AST, O
GT, O
Glucose, O
ST B-lipid
27:1;O, I-lipid
and O
Triglycerides O
System O
Reagent, O
(Beckman O
Coulter O
Biomedical). O

It O
was O
demonstrated O
that O
LysoPC O
(FA O
O-16:1) I-lipid
and O
LysoPC O
(22:5) O
(combined O
sensitivity O
and O
combined O
specificity, O
80.5 O
and O
80.1%, O
respectively) O
performed O
better O
compared O
with O
AFP O
(sensitivity O
and O
specificity, O
53 O
and O
64%, O
respectively) O
in O
the O
diagnosis O
of O
patients O
with O
HCC O
with O
<2 O
cm O
diameter O
tumors. O

5S,6S-(7E,9E,11Z,14Z)-dihydroxyeicosatetraenoic O
acid O
(1), O
FA B-lipid
20:4;O I-lipid
(2) O
and O
FA O
20:4;O O
(3) O
(Table O
6), O
α-tocopherol O
(4) O
γ-tocopherol O
(5), O
13-(6-hydroxy-2,7,8-trimethylchroman-2-yl)-2,6,10-trimethyltridecanoic O
acid O
(6), O
16-(4,5-dimethyl-3,6-dioxo O
cyclohexa-1,4-dienyl)-2,6,10,14-tetramethylhexadecanoic O
acid O
(7), O
6-hydroxy-2,7-dimethyl-2-(4,8,12-trimethyltridecyl)chroman-8-carbaldehyde O
(8), O
6-hydroxy-2,7-dimethyl-2-(4,8,12-trimethyltridecyl)chroman-8-carboxylic O
acid O
(9), O
calciferol O
(10), O
cholecalciferol O
(11), O
ergosterol O
(12), O
phylloquinone O
(13), O
retinol O
(14) O
and O
3β,7α-dihydroxy-5-cholestenoic O
acid O
(15). O

Quantification O
of O
endogenous O
lipid O
species O
was O
accomplished O
using O
multiple O
reaction O
monitoring O
(MRM) O
transitions O
that O
were O
developed O
in O
earlier O
studies O
[,] O
in O
conjunction O
with O
referencing O
to O
the O
signal O
intensities O
of O
known O
quantities O
of O
internal O
standards: O
PA B-lipid
28:0, I-lipid
PC B-lipid
28:0, I-lipid
PE B-lipid
28:0, I-lipid
phosphatidylglycerol O
(PG) O
15:0/15:0, O
phosphatidylinositol O
(PI) O
12:0/13:0, O
phosphatidylserine O
(PS) O
14:0/14:0, O
BMP B-lipid
28:0, I-lipid
acyl O
phosphatidylglycerol O
(APG) O
14:0/14:0/14:0, O
lysophosphatidylcholine O
(LPC) O

These O
diagnostic O
ions O
clearly O
suggested O
the O
existence O
of O
Δ9 O
and O
Δ11 O
C=C O
locations O
for O
the O
C18:1 O
chain O
of O
PE B-lipid
34:1, I-lipid
thus O
identifying O
the O
C=C O
location O
isomers O
as O
PE O
34:1(Δ9) O
and O
PE O
34:1(Δ11) O

We O
selected O
four O
metabolites O
as O
the O
potential O
predictive O
biomarkers O
for O
survival, O
based O
on O
CC<0.5 O
between O
each O
selected O
metabolite, O
which O
were O
Kynurenine, O
Acetylcarnitine, O
PC B-lipid
42:11, I-lipid
and O
LPE B-lipid
22:0 I-lipid
(Table O
). O

The O
colorectal O
cancer O
tissue O
samples O
also O
contained O
higher O
levels O
of O
lysophospholipids O
and O
fatty O
acids, O
especially O
stearic O
acid O
and O
polyunsaturated O
fatty O
acids, O
including O
arachidonic O
acid O
and O
FA B-lipid
22:6. I-lipid

report O
concentrations O
after O
consumption O
of O
JWH-018 O
and O
JWH-073, O
which O
were O
in O
the O
low O
nanogram O
per O
milliliter O
range O
for O
the O
main O
metabolites O
(JWH-018 O
5-hydroxypentyl O
23 O
ng/mL/26 O
ng/mL; O
JWH-018 O
FA B-lipid
5:0 I-lipid
16.5 O
ng/mL/16 O
ng/mL, O
JWH-073 O
FA B-lipid
4:0 I-lipid
6.2 O
ng/mL). O

The O
differentiated O
metabolites O
identified O
in O
the O
CD O
samples O
included O
tyrosine, O
an O
ornithine O
isomer, O
arachidonic O
acid, O
FA B-lipid
20:3, I-lipid
FA B-lipid
22:4, I-lipid
a O
sphingomyelin, O
a O
ceramide, O
and O
dimethylsphinganine. O

Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
were O
obtained O
from O
Avanti O
Polar O
Lipids O
(Alabaster, O
AL). O

The O
structure O
of O
the O
fatty O
acyl O
side O
chains O
was O
identified O
by O
MS/MS: O
Peak#1: O
PC B-lipid
38:4, I-lipid
Peak#2: O
PC O
38:4, O
Peak#3 O
& O
4: O
PC O
38:4 O
(See O
text O
for O
more O
details). O

The O
prohypertensive O
effects O
of O
either O
increased O
or O
decreased O
renal O
FA B-lipid
20:4;O I-lipid
production O
depends O
on O
the O
principal O
site, O
either O
a O
nephron O
segment O
such O
as O
the O
TAL O
(decreased O
FA O
20:4;O) O
or O
renal O
microvessels O
(increased O
FA O
20:4;O) O
as O
the O
afferent O
arteriole, O
that O
exhibits O
altered O
synthesis O
of O
FA O
20:4;O. O

Accordingly, O
in O
clinical O
settings, O
oxidized O
derivates O
of O
LA, O
such O
as O
9- O
and O
FA B-lipid
18:2;O, I-lipid
are O
correlated O
with O
NASH. O

Compared O
with O
the O
AUC_ROC O
value O
of O
the O
base O
model O
of O
BMI, O
history O
of O
hypertension, O
smoking, O
physical O
activity, O
triglycerides, O
and O
HDL O
cholesterol, O
no O
metabolites O
led O
to O
a O
significant O
increase O
in O
AUC O
values, O
whereas O
IDI O
and O
NRI O
statistics O
showed O
that O
dihomo-γ O
-linolenic O
acid O
and O
LPI B-lipid
16:1 I-lipid
could O
significantly O
improve O
risk O
reclassification O
of O
incident O
type O
2 O
diabetes O
at O
P O
< O
0.01. O

FA B-lipid
20:4;O I-lipid
is O
a O
pathway O
marker O
of O
anti-inflammatory O
and O
pro-resolving O
lipoxins O
(–). O

In O
a O
single O
sample O
Jager O
et O
al. O
found O
concentrations O
of O
8.7 O
ng/mL O
JWH-018 O
5-hydroxypentyl, O
0.89 O
ng/mL O
JWH-018 O
FA B-lipid
5:0, I-lipid
0.55 O
ng/mL O
JWH-073 O
FA B-lipid
4:0, I-lipid
0.67 O
ng/mL O
JWH-073 O
hydroxybutyl, O
and O
0.25 O
ng/mL O
JWH-250 O
FA O
5:0. O

FA B-lipid
10:0 I-lipid
(C10:0) O
increased O
at O
6 months O
post‐surgery O
compared O
with O
pre‐surgery O
values. O

h O
after O
the O
surgery O
(T24) O
of O
the O
patients O
(n O
 = 5); O
both O
are O
generated O
from O
FA B-lipid
20:5, I-lipid
biosynthesized O
by O
12-LOX O
and O
5-LOX; O
dotted O
lines O
represent O
the O
lower O
limit O
of O
quantification O
For O
COX O
derived O
metabolites, O
such O
as O
the O
prostaglandins O
and O
thromboxanes, O
no O
significant O
changes O
were O
observed O
in O
human O
plasma O
(Electronic O
Supplementary O
Material O
Fig. O

Maximum O
concentrations O
were O
845 O
ng/mL O
for O
JWH-018 O
5-hydroxypentyl, O
284 O
ng/mL O
for O
JWH-018 O
FA B-lipid
5:0, I-lipid
315 O
ng/mL O
for O
JWH-073 O
FA B-lipid
4:0, I-lipid
10 O
ng/mL O
for O
JWH-018 O
6-hydroxyindole, O
and O
6.2 O
ng/mL O
for O
JWH-073 O
4-hydroxybutyl. O

_– O
A O
double-blind O
randomized O
placebo-controlled O
study O
found O
that O
DHA O
or O
FA B-lipid
20:5 I-lipid
added O
to O
ARA O
supplementation O
could O
reduce O
behavioural O
problems O
in O
children O
with O
autism. O

The O
only O
PC O
lipid O
that O
is O
statistically O
significant O
and O
increased O
in O
fatal O
(F) O
vs. O
control O
(C) O
is O
PC B-lipid
32:0. I-lipid

LPC O
plasmalogen O
of O
m/z O
478 O
(LPC O
FA B-lipid
O-16:2) I-lipid
was O
the O
most O
relevant O
for O
predicting O
the O
response O
variable. O

In O
the O
present O
study, O
we O
provided O
evidence O
that O
there O
exists O
a O
relationship O
between O
lipids O
and O
OS O
in O
ovarian O
cancer, O
especially O
PC, O
LPC, O
LPE, O
and O
ceramides, O
and O
we O
chose O
the O
PC B-lipid
42:11 I-lipid
and O
LPE B-lipid
22:0 I-lipid
as O
the O
important O
potential O
biomarkers O
to O
predict O
the O
OS O
of O
ovarian O
cancer. O

A) O
MRM O
profile O
of O
12 O
eicosanoid O
and O
docosanoid O
synthetic O
standards O
(NPD1, O
4-HDHA, O
17-HDHA, O
RVD1, O
PGE_2 O
, O
PGD_2 O
, O
LTB_4 O
, O
6-trans O
LTB_4 O
(C1), O
6-trans-12-epi-LTB_4 O
(C2), O
FA B-lipid
20:4;O, I-lipid
FA O
20:4;O, O
5-HETE). O

The O
potential O
implication O
of O
LysoPC O
metabolism O
in O
SR O
was O
further O
reinforced O
by O
the O
finding O
of O
LPC B-lipid
20:4 I-lipid
as O
a O
potential O
biomarker O
of O
SR O
based O
on O
ROC O
curves O
of O
aggregated O
cohorts. O

Of O
the O
differentially O
produced O
metabolites O
among O
the O
3 O
groups, O
24 O
metabolites O
(2-hydroxy-3-methylbutyric O
acid, O
3,4-dihydrxoybutyric O
acid, O
4-hydroxybutyric O
acid, O
6-aminocaproic O
acid, O
arabionse, O
arabitol, O
cellobiose, O
cytidine O
5′-diphosphocholine, O
ethanolamine, O
glyceraldehyde, O
GCDCA-3-sulfate, O
hydroxyprolyl-methionine, O
hypoxanthine, O
Ile-Thr, O
indole-3-acetamide, O
isoleucine, O
lactic O
acid, O
myo-inositol, O
FA B-lipid
5:0, I-lipid
threitol, O
threoninyl-methionine, O
trimethylamine O
N-oxide O
(TMAO), O
uridine, O
and O
valine) O
were O
consistently O
higher O
or O
lower. O

Among O
those, O
only O
two O
overlapped O
with O
the O
ones O
exhibiting O
significant O
changes O
at O
subclass O
level O
analysis, O
i.e. O
PC B-lipid
34:1 I-lipid
and O
PE B-lipid
36:1. I-lipid

The O
mean O
values O
of O
most O
traits O
fell O
within O
the O
normal O
range, O
with O
the O
exception O
of O
low-density O
lipoprotein O
(LDL) O
cholesterol O
(121 O
mg/dL), O
which O
was O
higher O
than O
the O
level O
recommended O
by O
the O
National O
ST B-lipid
27:1;O I-lipid
Education O
Program O
of O
the O
United O
States O
(< O
100 O
mg/dL). O

The O
other O
product O
ion O
in O
the O
spectrum O
appeared O
at O
m/z O
279 O
provides O
the O
information O
about O
one O
of O
the O
acyl O
moiety O
of O
the O
PE O
as O
FA B-lipid
18:3. I-lipid

collision O
energy O
12 O
eV, O
8iPGF_3 O
351.0 O
->193.0, O
collision O
energy O
22 O
eV, O
20-COOH-LTB_4 O
365.0 O
->195.0, O
collision O
energy O
13 O
eV, O
RvD1, O
RvD2 O
375.0 O
->141.3, O
collision O
energy O
13 O
eV; O
RvE1 O
375.1 O
->141.3, O
collision O
energy O
13 O
eV; O
from O
9.0–12.5 O
min O
for O
FA B-lipid
18:2;O I-lipid
294.7 O
->170.7, O
collision O
energy O
16 O
eV; O
FA O
18:2;O O
294.7 O
->194.7, O
collision O
energy O
16 O
eV; O
FA B-lipid
20:5;O I-lipid
317.0 O
->115.0, O
collision O
energy O
17 O
eV; O
FA O
20:5;O O
317.0 O
->179.0, O
collision O
energy O
17 O
eV; O
FA O
20:5;O O
317.0 O
->219.0, O
collision O
energy O
17 O
eV, O
LTC_4 O
623.9 O
->272.0, O
collision O
energy O
14 O
eV O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->279.0, O
collision O
energy O
10 O
eV; O
8-HEPE O
317.0 O
->255.0, O
collision O
energy O
17 O
eV, O
FA O
20:5;O O
317.0 O
->259.0, O
collision O
energy O
17 O
eV; O
5-oxoETE, O
12-oxoETE O
and O
15-oxoETE O
317.0 O
->273.0, O
collision O
energy O
17 O
eV, O
FA B-lipid
20:4;O I-lipid
319.0 O
>245.0, O
collision O
energy O
10 O
eV; O
LTC_4 O
623.9 O
->272.0, O
collision O
energy O
14 O
eV; O
LTE_4 O
438.0 O
->333.0, O
collision O
energy O
13 O
eV O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->59.2, O
collision O
energy O
25 O
eV; O
EPA O
301.0 O
->203.2, O
collision O
energy O
12 O
eV; O
AA O
303.0 O
->259.3, O
collision O
energy O
11 O
eV, O
DHA O
327.1 O
->29.3, O
collision O
energy O
14 O
eV. O
Method O
B O
from O
0.0–9.8 O
min O
for O
PGE_2 O
, O
d15d12PGD_2 O
, O
PGD_2 O
, O
d15d12PGJ_2 O
, O
PGJ_2 O
315.0 O
->271.3, O
collision O
energy O
13 O
eV; O
LTB_5 O
333.0 O
->195.0, O
collision O
energy O
13 O
eV; O
LTB_4 O
335.0 O
->195.0, O
collision O
energy O
13 O
eV; O
RvE_1 O
349.1 O
->195.3, O
collision O
energy O
13 O
eV; O
HXA_3 O
, O
HXB_3 O
, O
20-COOH-AA O
335.0 O
->273.3, O
collision O
energy O
13 O
eV; O
LXA_5 O
349.0 O
->115.0, O
collision O
energy O
12 O
eV; O
20-OH-LTB_4 O
351.0 O
->195.0, O
collision O
energy O
13 O
eV; O
MaR O
359.0 O
->250.0, O
collision O
energy O
13 O
eV; O
from O
9.8–12.5 O
min O
for O
FA O
20:4;O O
318.7 O
->115.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->155.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->167.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->179.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->218.9, O
collision O
energy O
11 O
eV; O
4-HDHA O
343.0 O
->101.0, O
collision O
energy O
10 O
eV; O
10-HDHA O
343.0 O
->181.0, O
collision O
energy O
10 O
eV; O
14-HDHA O
343.0 O
->205.0, O
collision O
energy O
10 O
eV; O
17-HDHA O
343.0 O
->245.0, O
collision O
energy O
14 O
eV, O
20-HDHA O
343.0 O
->285.0, O
collision O
energy O
10 O
eV; O
13-oxoODE O
293.0 O
->249.0, O
collision O
energy O
17 O
eV O
and O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->59.2, O
collision O
energy O
25 O
eV; O
EPA O
301.0 O
->203.2, O
collision O
energy O
12 O
eV, O
AA O
303.0 O
->259.3, O
collision O
energy O
11 O
eV, O
DHA O
327.1 O
->229.3, O
collision O
energy O
14 O

Interestingly, O
plasma O
SM O
levels O
(SM O
36:1, O
SM B-lipid
38:1;O2, I-lipid
and O
SM B-lipid
40:1;O2), I-lipid
which O
are O
related O
with O
fatty O
liver O
and O
insulin O
resistance O
as O
well O
as O
obesity, O
were O
significantly O
elevated O
in O
pre-diabetic O
individuals O
with O
AO O
when O
compared O
to O
normal O
individuals O
with O
AO O
or O
pre-diabetic O
without O
AO O
( O
and O
). O

Parts O
of O
the O
peaks O
were O
identified O
as O
1, O
lactic O
acid; O
2, O
alanine; O
3, O
valine; O
4, O
leucine; O
5, O
proline; O
6, O
glycine; O
7, O
uracil; O
8, O
fumaric O
acid; O
9, O
serine; O
10, O
threonine; O
11, O
malic O
acid; O
12, O
pyroglutamic O
acid; O
13, O
asparagine; O
14, O
hydroxyproline; O
15, O
creatinine; O
16, O
ornithine; O
17, O
glutamic O
acid; O
18, O
phenylalanine; O
19, O
ribose; O
20, O
glutamine; O
21, O
hypoxanthine; O
22, O
glucose; O
23, O
FA B-lipid
16:0; I-lipid
24, O
linoleic O
acid; O
25, O
oleic O
acid; O
26, O
tryptophan; O
27, O
stearic O
acid; O
28, O
glucose-6-phosphate; O
29, O
maltose; O
and O
30, O
cholesterol. O

MS/MS O
spectra O
of O
the O
earlier O
eluting O
isomer O
of O
PC B-lipid
40:6 I-lipid
implied O
contribution O
of O
two O
species O
(PC O
40:6 O
and O
PC O
40:6) O
to O
a O
single O
chromatographic O
peak. O

Young O
women O
had O
higher O
concentration O
of O
DPA O
and O
FA B-lipid
20:4;O I-lipid
than O
young O
men O
(a O
and O
b). O

PC B-lipid
40:7 I-lipid
is O
annotated O
by O
the O
algorithm O
whereas O
SM B-lipid
36:3;O2 I-lipid
was O
characterised O
by O
MS/MS O
analysis O
using O
Li O
infusion. O

The O
m/z O
279.2329 O
as O
the O
base O
peak O
indicated O
that O
FA B-lipid
18:2 I-lipid
located O
at O
sn O
-2 O
position O
on O
the O
glycerol O
backbone, O
as O
it O
is O
known O
that O
fragment O
ion O
ratio O
of O
[FA_1 O
-H]_− O
/[FA_2 O
-H]_− O
is O
less O
than O
1 O
[, O
, O
]. O

[FA O
24:1 I-lipid
or O
24:1, O
n O
-9 O
by O
the O
International O
Union O
of O
Pure O
and O
Applied O
Chemistry O
nomenclature] O
is O
a O
long O
chain O
of O
monounsaturated O
omega-9 O
fatty O
acids O
that O
are O
particularly O
abundant O
in O
the O
white O
matter O
of O
the O
brain. O

However, O
in O
the O
sera, O
we O
observed O
high O
levels O
of O
SM B-lipid
16:0;O2 I-lipid
in O
MF O
patients. O

Stability O
of O
FA B-lipid
20:4;O I-lipid
and O
deuterated O
FA O
20:4;O-d_11 O
decreased O
to O
61 O
and O
57%, O
respectively, O
at O
this O
storage O
condition O
for O
plasma O
extract O
at O
24 O
h O
relative O
to O
0 O
h. O

PC B-lipid
40:7 I-lipid
(A) O
and O
SM B-lipid
36:3;O2 I-lipid
(B) O
at O
w0, O
w16 O
and O
w28. O

The O
abnormal O
levels O
of O
the O
fatty O
acids O
(linolenic O
acid, O
linoleic O
acid, O
oleic O
acid, O
and O
arachidonic O
acid) O
and O
lysoPCs O
(lysoPC O
(14:0), O
LPC B-lipid
16:0, I-lipid
lysoPC O
(16:1), O
lysoPC O
(18:0) O
and O
lysoPC O
(20:3)) O
in O
ESCC O
patients O
are O
indicative O
of O
disturbed O
lipid O
and O
energy O
metabolism. O

Indeed, O
4/20 O
HCC O
patients O
had O
inordinately O
high O
LPA B-lipid
16:0 I-lipid
plasma O
levels O
and O
that O
LPA O
16:0 O
strongly O
correlated O
with O
plasma O
AFP O
concentrations. O

FAA, O
fatty O
acid O
amide; O
POEA, O
palmitoleoyl O
ethanolamide; O
LPC, O
lysophosphatidylcholine; O
PC, O
phosphatidylcholine; O
PE, O
phosphatidylethanolamine; O
SM, O
sphingomyelin; O
Cer, O
ceramide; O
CE, O
cholesterol O
ester; O
CoQ10, O
coenzyme O
Q10; O
DGLA, O
dihomo-γ-linoleic O
acid; O
AA, O
arachidonic O
acid; O
FA B-lipid
20:3;O2, I-lipid
8,9-dihydroxy-5Z O
,11Z O
,14Z O
-eicosatrienoic O
acid; O
EPA, O
FA B-lipid
20:5 I-lipid
(20:5;5Z O
,8Z O
,11Z O
,14Z O
,17Z O
); O
FA B-lipid
20:5;O, I-lipid
12-hydroxy-5Z O
,8Z O
,10E,14Z O
,17Z O
-FA O
20:5; O
12-LOX, O
12-lipoxygenase; O
PGE2, O
prostaglandin O
E2; O
PGF2α, O
prostaglandin O
F2α; O
PGF1α, O
prostaglandin O
1α; O
TxB2, O
thromboxane O
B2; O
TxA2, O
thromboxane O
A2; O
mPGES-1, O
microsomal O
prostaglandin O
E O
synthase-1; O
2OG, O
2-oxoglutarate; O
2HG, O
(R O
)-2-hydroxyglutarate; O
DIC, O
disseminated O
intravascular O
coagulation; O
PGH2, O
prostaglandin O
H2 O

Calibration O
standards O
were O
prepared O
by O
spiking O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
working O
solution O
into O
5% O
BSA O
in O
water O
and O
plasma, O
to O
the O
final O
concentrations O
consisting O
of O
Cer O
22:0;O2 O
and O
Cer O
24:0;O2 O
at O
0.02/0.08, O
0.05/0.2, O
0.1/0.4, O
0.2/0.8, O
0.5/2, O
1/4, O
2/8, O
4/16 O
μg/mL, O
respectively, O
by O
serial O
dilution. O

A O
Kruskal-Wallis O
test O
of O
the O
individual O
time-points O
for O
each O
of O
the O
selected O
candidate O
markers O
revealed O
that O
most O
of O
them O
can O
be O
detected O
postprandially O
at O
more O
than O
one O
time-point O
between O
1 O
and O
6 O
h O
(lactose, O
galactose, O
galactitol, O
galactonate, O
galactono-1,5-lactone, O
methionine, O
proline, O
3-phenyllactic O
acid, O
FA B-lipid
12:0, I-lipid
linoleic O
acid, O
γ-tocopherol, O
maltol, O
sucrose, O
unknown O
S13, O
unknown O
S27), O
their O
presence O
in O
serum O
being O
no O
longer O
detected O
at O
24 O
h O
(Table O
S3). O

Another O
metabolite O
associated O
with O
both O
oral O
fat O
intake O
and O
NRI O
score O
was O
SM B-lipid
42:1;O2. I-lipid

In O
mismatch O
repair-proficient O
cell O
lines O
(SW480, O
SW620, O
HT-29, O
NCM460), O
higher O
levels O
of O
PC B-lipid
34:1 I-lipid
and O
phosphatidic O
acid O
(18:0/18:0) O
were O
detected, O
as O
compared O
with O
mismatch O
repair-deficient O
cell O
lines O
(HCT-116, O
DLD1, O
LoVo, O
HCT15). O

Within O
aldehydes, O
FAL B-lipid
13:0 I-lipid
showed O
the O
highest O
level O
in O
the O
fecal O
samples O
of O
HC. O

The O
later O
eluting O
isomer O
of O
PC B-lipid
40:6 I-lipid
coeluted O
with O
our O
standard, O
PC O
40:6. O

In O
this O
study O
we O
observed O
an O
increase O
in O
only O
a O
single, O
minor O
SM O
having O
two O
C18 O
chains O
with O
one O
and O
two O
double O
bonds, O
respectively, O
either O
SM B-lipid
36:3;O2 I-lipid
or O
SM O
36:3;O2. O

ROC O
curves O
of O
volatile O
biomarkers O
for O
the O
diagnosis O
of O
(A) O
B-NHL O
from O
non-lymphoma, O
(B) O
B-NHL O
from O
healthy O
control, O
(C) O
aggressive O
B-NHL O
from O
indolent O
B-NHL, O
(D) O
CD20_+ O
B-NHL O
from O
CD20_− O
B-NHL, O
(E) O
early-stage O
B-NHL O
from O
advanced O
B-NHL O
using O
different O
combinations O
of O
4-heptanone, O
2-methylpyrazine, O
FAL B-lipid
5:0, I-lipid
2,6-dimethyl-7-octen-2-ol O
and O
FA B-lipid
10:0. I-lipid

We O
have O
developed O
a O
label O
free O
untargeted O
LC-MS-based O
lipidomic O
workflow O
that O
combines O
the O
following O
characteristics: O
(i) O
untargeted O
MS O
data O
acquisition O
to O
enable O
its O
use O
in O
biomarker O
discovery, O
(ii) O
optimized O
extraction O
recovery O
across O
multiple O
classes O
of O
polar O
and O
non-polar O
lipids O
(for O
e.g. O
glycerophospholipids O
vs. O
glycerolipids), O
(iii) O
chromatographic O
resolution O
within O
lipid O
isomers O
characterized O
by O
fatty O
acyl O
side O
chains O
of O
different O
chain O
length O
(for O
e.g. O
PC B-lipid
38:6 I-lipid
and O
PC O
38:6), O
or O
position O
of O
double O
bonds O
(for O
e.g. O
PC(18:0_20:4n-3 O
) O
and O
PC(18:0_20:4n-6 O
)), O
(iv) O
data O
processing O
method O
that O
incorporated O
scripts O
to O
optimize O
MS O
data O
alignment, O
filtering O
and O
correction, O
and O
(v) O
lipid O
identification, O
including O
acyl O
side O
chains, O
through O
MS/MS. O

Our O
previous O
studies O
have O
shown O
that O
DG B-lipid
34:2 I-lipid
is O
comprised O
mainly O
of O
DG O
34:2 O
while O
DG B-lipid
36:2 I-lipid
is O
66% O
DG O
36:2 O
and O
33% O
DG O
36:2, O
with O
no O
differences O
in O
fatty O
acid O
composition O
of O
these O
DAGs O
between O
aged-matched O
control, O
MCI O
and O
LOAD O
subjects O
. O

The O
absolute O
concentration O
(ng/mL) O
of O
each O
PC O
was O
calculated O
based O
on O
the O
peak O
area O
of O
the O
PC O
identified O
in O
the O
sample O
and O
the O
peak O
area O
of O
the O
internal O
standard O
of O
PC B-lipid
33:1 I-lipid
corresponding O
to O
the O
sample O
(the O
formula O
was O
shown O
in O
Figure _S1 O
). O

Applying O
the O
same O
criteria O
used O
for O
the O
plasma O
lipidome O
to O
select O
the O
biomarker O
candidates, O
five O
lipids, O
LPC B-lipid
16:1, I-lipid
PC B-lipid
33:1, I-lipid
PC O
(35:4)B, O
PC O
(36:5)B O
and O
PC B-lipid
36:6, I-lipid
discriminated O
meloxicam-treated O
from O
saline-treated O
cats. O

Neither O
of O
the O
recent O
studies O
evaluated O
longitudinal O
diabetes O
incidence O
data; O
however, O
Huynh O
et O
al. O
demonstrated O
a O
significant O
correlation O
between O
1 O
of O
our O
putative O
prognostic O
markers, O
SM B-lipid
36:1;O2, I-lipid
and O
fasting O
glucose. O

By O
way O
of O
contrast, O
FA B-lipid
20:4;O, I-lipid
which O
inhibits O
Na_+ O
-K_+ O
-2Cl_− O
cotransporter O
activity O
in O
the O
TAL, O
will O
promote O
Na_+ O
reabsorption O
and O
elevate O
blood O
pressure O
when O
deficient, O
as O
in O
the O
Dahl O
salt-sensitive O
rat. O

This O
measurement O
also O
explains O
the O
detection O
of O
a O
low O
abundance O
peak O
at O
m O
/z O
445 O
from O
the O
PC B-lipid
34:1 I-lipid
sample, O
which O
is O
actually O
the O
sn O
-1 O
fragment O
derived O
from O
PC O
34:1. O

The O
fraction O
of O
heavy O
chains O
for O
PC B-lipid
34:1 I-lipid
is O
given O
by O
(0.55 O
+ O
2 O
× O
0.28) O
/ O
2 O
= O
0.55. O

The O
levels O
of O
FA B-lipid
20:4;O I-lipid
cannot O
be O
accurately O
estimated O
because O
of O
its O
lability. O

Sphingolipids O
that O
were O
lower O
in O
OIR O
versus O
Lean O
included O
the O
most O
and O
second O
most O
abundant O
Hex2Cer(d18:1/16:0) O
and O
Hex2Cer(d18:1/24:1), O
5 O
of O
6 O
Hex3Cer O
including O
the O
most O
abundant O
Hex3Cer(d18:1/16:0) O
and O
the O
two O
most O
abundant O
GM3 O
GM3(d18:1/16:0) O
and O
GM3 B-lipid
42:2;O2. I-lipid

SM O
36:0 O
and O
DG B-lipid
36:2 I-lipid
were O
retained O
in O
the O
final O
glucose O
model, O
together O
accounting O
for O
6.1% O
of O
the O
variation O
in O
change O
in O
glucose O
(baseline O
glucose O
explained O
22.1%). O

For O
example, O
FA B-lipid
20:4;O I-lipid
reduced O
TNFɑ-induced O
VCAM-1 O
surface O
expression O
in O
HAEC. O

For O
the O
oxylipins, O
the O
RSD O
values O
ranged O
from O
4 % O
up O
to O
15 % O
with O
exceptions O
for O
FA B-lipid
20:4;O I-lipid
(41 %), O
9,12,13-TriHOME O
(32 %), O
and O
16(17)-EpDPE O
(21 %). O

The O
two O
minor O
markers O
have O
peaks O
with O
a O
RT O
slightly O
different O
from O
the O
main, O
18:0 O
containing O
PC(40:6) O
and O
PC B-lipid
38:4 I-lipid
peaks, O
indicating O
that O
they O
may O
be O
detectable O
due O
to O
better O
signal-to-noise O
ratio O
for O
these O
specific O
compounds, O
but O
the O
more O
prominent O
PC B-lipid
40:7 I-lipid
marker O
is O
actually O
dominating O
the O
only O
PC O
40:7 O
peak O
observed O
and O
the O
level O
in O
the O
non-TFA O
group O
is O
quite O
low. O

In O
the O
present O
study, O
leukotriene O
B_4 O
and O
FA B-lipid
20:4;O I-lipid
levels O
were O
significantly O
lower O
in O
the O
LC O
group O
than O
the O
control O
group O
and O
the O
leukocyte O
number O
in O
the O
LC O
group O
had O
a O
trend O
toward O
decrease O
compared O
to O
the O
control O
group. O

Also, O
our O
short-term O
results O
are O
in O
line O
with O
a O
recently O
published O
study O
which O
showed O
an O
increase O
of O
PC B-lipid
38:6 I-lipid
in O
the O
first O
42 O
days O
after O
bariatric O
surgery. O

The O
absolute O
concentrations O
(ng/ml) O
of O
each O
PC O
and O
PE O
were O
calculated O
based O
on O
the O
peak O
areas O
of O
the O
PC O
and O
PE O
identified O
in O
the O
sample O
and O
the O
peak O
areas O
of O
the O
internal O
standards O
of O
PC B-lipid
33:1 I-lipid
and O
PE B-lipid
33:1 I-lipid
corresponding O
to O
the O
sample. O

Among O
the O
statistically O
significant O
correlations, O
lauric O
acid O
(C12:0), O
FA B-lipid
15:0 I-lipid
(C15:0), O
stearic O
acid O
(C18:0), O
myristoleic O
acid O
(C14:1), O
cis-10 O
FA O
15:0 O
(C15:1) O
and O
arachidonic O
acid O
(C20:4n6) O
were O
stronger O
correlated O
in O
the O
case O
than O
the O
control O
group O
(p O
< O
0.001). O

In O
addition, O
4 O
organic O
acids O
(i.e., O
4-HPA, O
1,2-cyclopentanedicarboxylic O
acid O
(dimethyl), O
FA B-lipid
3:0;O, I-lipid
and O
2-aminophenylacetic O
acid) O
were O
all O
found O
to O
be O
increased. O

The O
EET O
pair O
displayed O
a O
slight O
difference O
in O
retention O
time O
(ΔRT=0.1) O
and O
the O
reported O
fragment O
ion O
m/z O
167 O
(red, O
) O
can O
be O
found O
in O
both O
FA B-lipid
20:4;O I-lipid
and O
FA O
20:4;O. O

The O
six O
metabolite O
panel O
consisted O
of O
5-hydroxytryptophan, O
LPE B-lipid
18:2, I-lipid
PC B-lipid
32:0, I-lipid
PC B-lipid
40:4, I-lipid
PE B-lipid
17:0, I-lipid
and O
SM B-lipid
34:1;O2 I-lipid
(Table O
). O

For O
the O
classification O
between O
the O
two O
groups, O
m-cresol, O
benzene, O
FAL B-lipid
9:0 I-lipid
and O
acetone O
seem O
to O
be O
the O
most O
likely O
VOM O
to O
identify O
patients O
with O
malignant O
neoplasia O
in O
the O
head O
and O
neck O
region. O

The O
MS/MS O
spectrum O
of O
[M-H]- O
ion O
of O
FA B-lipid
20:4 I-lipid
is O
shown O
in O
. O

C-reactive O
protein O
is O
an O
acute-phase O
inflammatory O
protein, O
which O
showed O
a O
positive O
correlation O
with O
FA B-lipid
22:6;O, I-lipid
a O
FA O
22:6 O
(DHA) O
lipid O
peroxidation O
metabolite. O

The O
levels O
of O
PE B-lipid
34:3, I-lipid
PE B-lipid
34:0, I-lipid
PE B-lipid
35:2, I-lipid
PE B-lipid
35:1, I-lipid
PE B-lipid
36:4, I-lipid
PE B-lipid
36:3, I-lipid
PE B-lipid
36:1, I-lipid
PE B-lipid
38:5, I-lipid
PC B-lipid
36:6, I-lipid
and O
PC B-lipid
38:1 I-lipid
in O
LBD O
were O
significantly O
increased O
compared O
with O
HC O
(p<0.05). O

It O
is O
observed O
that O
pyridoxine O
levels O
are O
lowered O
in O
the O
stages O
of O
II, O
III, O
and O
IV O
as O
compared O
to O
stage O
0 O
and O
I. O
ST B-lipid
27:1;O, I-lipid
taurocholic O
acid, O
and O
deoxycholic O
acid O
are O
three O
related O
metabolites O
participating O
in O
bile O
acid O
biosynthesis O
whose O
levels O
had O
increased O
in O
the O
II O
and O
III O
stage O
groups. O

HPLC-MS/MS, O
dMRM, O
FA B-lipid
20:4;O, I-lipid
FA B-lipid
20:5;O I-lipid

The O
two O
dhSMs O
positively O
associated O
with O
obesity O
– O
SM O
36:0 O
and O
SM B-lipid
42:0;O2 I-lipid
– O
were O
also O
positively O
associated O
with O
dysglycemia, O
along O
with O
Cer B-lipid
42:0;O2. I-lipid

FA O
and O
neurosteroids O
were O
increased O
in O
MSA, O
and O
LPC B-lipid
16:0, I-lipid
and O
oxidative O
stress O
markers O
were O
changed O
in O
PSP. O

(A) O
K-M O
survival O
curve O
of O
among O
the O
different O
groups O
by O
the O
3 O
selected O
serum O
metabolites O
(FA O
6:2, I-lipid
4-methylphenyl O
dodecanoate O
and O
glycerol O
tributanoate) O
together; O
(B) O
K-M O
survival O
curve O
of O
among O
the O
different O
groups O
by O
FA O
6:2 O
only; O
(C) O
K-M O
survival O
curve O
of O
among O
the O
different O
groups O
by O
4-methylphenyl O
dodecanoate O
only; O
(D) O
K-M O
survival O
curve O
of O
among O
the O
different O
groups O
by O
glycerol O
tributanoate O
only. O

A O
panel O
of O
metabolite O
markers O
composed O
of O
biotin O
sulfone, O
FA B-lipid
21:1;O, I-lipid
d-glucosaminide O
and O
2-methylhippuric O
acid O
was O
selected, O
which O
was O
able O
to O
discriminate O
HBV O
subjects O
from O
their O
healthy O
counterparts. O

The O
mean O
concentrations O
of O
LPC B-lipid
16:1 I-lipid
were O
similar O
and O
tightly O
grouped O
in O
each O
study O
group O
and O
showed O
no O
statistically O
significant O
differences. O

Abbreviations: O
MSA: O
multiple O
system O
atrophy; O
AUC: O
area O
under O
the O
curve; O
FA: O
fatty O
acid; O
LPC B-lipid
16:0: I-lipid
lysophosphatidylcholine O
(16:0); O
DHEAS: O
dehydroisoandrosterone O
3-sulfate O

Chief O
among O
them O
are O
several O
GPLs O
that O
are O
believed O
to O
have O
biological O
significance O
in O
cancer O
physiology, O
including O
PC B-lipid
32:1, I-lipid
PC B-lipid
34:1, I-lipid
PS B-lipid
38:5, I-lipid
PE B-lipid
38:6, I-lipid
PC B-lipid
32:3, I-lipid
and O
PC(34:2)._5 O
, O

In O
terms O
of O
clinical O
applicability, O
LPG B-lipid
20:5 I-lipid
arose O
as O
a O
potential O
EOC O
recurrence O
predictive O
biomarker O
to O
increase O
the O
predictive O
power O
of O
clinical O
predictors O
from O
AUC O
value O
0.739 O
to O
0.875. O

In O
a O
similar O
way, O
the O
PC B-lipid
37:5 I-lipid
(MS/MS O
of O
m/z O
852.5745) O
can O
be O
confirmed, O
proposing O
the O
presence O
of O
the O
molecular O
species; O
PC O
37:5, O
PC B-lipid
O-38:5, I-lipid
PC O
O-38:5 O
and O
PC O
O-38:5 O
(C O
and O
). O

As O
we O
were O
able O
to O
detect O
slightly O
higher O
levels O
of O
the O
COX-2 O
byproducts, O
FA B-lipid
20:4;O, I-lipid
13-HDHA, O
and O
17-HDHA, O
in O
individuals O
under O
statin O
treatment O
compared O
with O
untreated O
or O
ASA-treated O
subjects, O
there O
could O
be O
a O
combined O
effect O
of O
statin O
treatment O
to O
induce O
COX-2 O
expression O
and O
activation O
by O
S-nitrosylation O
leading O
to O
increased O
formation O
of O
FA O
20:4;O, O
13-HDHA, O
and O
17-HDHA O
(, O
, O
). O

As O
shown O
in O
, O
LPA B-lipid
18:2, I-lipid
LPC O

For O
example, O
FA B-lipid
20:4;O, I-lipid
FA O
20:4;O O
and O
FA O
20:4;O O
did O
not O
resolve O
well O
with O
a O
ΔRT O
of O
0.07 O
min. O

Significant O
changes O
in O
FA B-lipid
20:5 I-lipid
(EPA) O
or O
FA B-lipid
22:6 I-lipid
(DHA) O
(P O
value = 0.59 O
and O
0.65, O
respectively) O
in O
serum O
following O
RYGB O
were O
not O
observed. O

Two O
pairs O
of O
regioisomers, O
FA B-lipid
20:4;O I-lipid
and O
FA O
20:4;O O
(319 O
> O
167), O
7-HDHA O
and O
17-HDHA O
(343 O
> O
245) O
were O
nearly O
baseline O
separated. O

The O
overweight O
group O
showed O
significant O
decreases O
in O
11 O
metabolites—lysoPCs O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:2, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
and O
PC O
(18:0/20:4)—and O
significant O
increases O
in O
6 O
metabolites—L-leucine, O
palmitic O
amide, O
L-octanoylcarnitine, O
decanoylcarnitine, O
PC B-lipid
36:4, I-lipid
and O
lactosylceramide. O

The O
collision O
activated O
dissociation O
product O
ion O
spectrum O
of O
the O
[M+H]_+ O
ion O
of O
Cer B-lipid
22:0;O2 I-lipid
at O
m/z O
622 O
and O
proposed O
structures O
of O
the O
fragment O
ions O
are O
shown O
in O
. O

Such O
effective O
mechanism O
might O
results O
in O
the O
activation O
and O
successful O
antioxidative O
response, O
as O
displayed O
by O
the O
decreased O
concentration O
of O
FA B-lipid
18:2;O, I-lipid
and O
9-oxoODE O
in O
centenarians. O

Our O
data O
in O
centenarians O
support O
promotion O
of O
cellular O
detoxification O
mechanisms O
through O
specific O
modulation O
of O
the O
arachidonic O
acid O
metabolic O
cascade O
as O
we O
underpinned O
increased O
concentration O
of O
FA B-lipid
20:4;O, I-lipid
suggesting O
enhanced O
cytochrome O
P450 O
(CYP) O
enzyme O
activity. O

Subjects O
with O
RVD O
exhibited O
increased O
plasma O
FA B-lipid
20:4;Os, I-lipid
reduced O
excretion O
of O
FA O
20:4;O, O
decreased O
plasma O
EETs, O
and O
increased O
plasma O
DHETs. O

Finally, O
in O
contrast O
to O
the O
AA O
canonical O
eicosanoid O
cascade, O
leading O
to O
the O
metabolites O
discussed O
above, O
data O
from O
the O
parallel O
pathway O
starting O
with O
FA B-lipid
20:5 I-lipid
(EPA; O
20:5n-3) O
was O
also O
collected O
(Supplemental O
Fig. O
11C). O

A O
pooled-plasma O
sample O
was O
analyzed O
to O
establish O
the O
mean O
concentration O
of O
endogenous O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
by O
the O
LC/MS/MS O
method. O

However, O
arachidonic O
acid O
(ARA, O
20:4) O
and O
FA B-lipid
22:6 I-lipid
(DHA O
22:6), O
which O
are O
long-chain O
polyunsaturated O
acids O
(PUFAs), O
were O
decreased O
in O
R_AT O
and O
R_BT O
, O
respectively O
(Shown O
in O
Figures O
, O
). O

Due O
to O
the O
endogenous O
presence O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
in O
human O
plasma, O
5% O
BSA O
in O
water O
was O
used O
to O
prepare O
the O
calibration O
standards. O

Our O
results O
of O
higher O
FA B-lipid
20:4;O I-lipid
levels O
in O
serum O
than O
in O
plasma O
corroborate O
earlier O
investigations O
[, O
, O
]. O

Several O
serum O
and O
urine O
metabolites O
as O
potential O
markers O
in O
a O
small O
number O
of O
HCC O
patients O
(n O
= O
20) O
were O
identified O
by O
gas O
chromatography O
mass O
spectrometry O
(GC-MS, O
LC-MS) O
(, O
), O
including O
nucleosides, O
FA B-lipid
4:0, I-lipid
ethanimidic O
acid, O
glycerol, O
isoleucine, O
valine, O
aminomalonic O
acid, O
glycine, O
tyrosine, O
threonine, O
etc. O

To O
date, O
FA B-lipid
10:0 I-lipid
has O
not O
been O
reported O
to O
be O
a O
biomarker O
of O
cancer. O

[LPC O
(FA O
O-16:2)], I-lipid
with O
highest O
variable O
importance O
projection O
score, O
showed O
a O
tendency O
to O
be O
lower O
in O
the O
cancer O
patients. O

Taken O
together, O
these O
data O
suggest O
that O
SM B-lipid
36:1;O2, I-lipid
SM B-lipid
38:1;O2 I-lipid
and O
SM B-lipid
40:1;O2 I-lipid
among O
lipid O
species O
might O
be O
putative O
diagnostic O
markers O
in O
pre-diabetic O
patients O
with O
AO. O

Among O
them O
serum O
lipid O
signatures O
identified O
in O
this O
study O
PC B-lipid
39:6 I-lipid
and O
FA B-lipid
22:3 I-lipid
together O
showed O
higher O
sensitivity, O
specificity O
and O
accuracy O
in O
differentiation O
of O
PCa O
specimens O
from O
normal O
compared O
to O
other O
lipids O
in O
possible O
combinations. O

However, O
there O
are O
several O
standards O
with O
S/N O
less O
than O
1500; O
FA B-lipid
7:0 I-lipid
(S/N O
= O
18), O
FA B-lipid
10:0 I-lipid
(S/N O
= O
83), O
oxalic O
acid O
(S/N O
= O
47) O
and O
adipic O
acid O
(S/N O
= O
87). O

IS O
 = 0.6 ± 0.4, O
N = 6) O
for O
relative O
quantitation O
of O
PE B-lipid
34:1. I-lipid

Negative O
ion O
CTS O
analysis O
of O
phospholipid O
standards O
(PC, O
PE, O
PA, O
PS, O
and O
PI) O
containing O
FA B-lipid
17:0 I-lipid
(17:0) O
esterified O
to O
the O
sn O
-1 O
position O
of O
the O
glycerol O
backbone O
and O
arachidonic O
acid O
(20:4) O
at O
the O
sn O
-2 O
position O
of O
the O
glycerol O
backbone O
and O
the O
sphingomyelin O
standard, O
SM B-lipid
36:1;O2, I-lipid
was O
completed. O

Examples O
of O
some O
of O
the O
other O
compounds O
that O
could O
be O
tentatively O
matched O
to O
the O
elemental O
formulae O
obtained O
in O
this O
investigation O
include O
FA B-lipid
17:2;O, I-lipid
palmitic O
acid, O
stearic O
acid, O
GlnHisAla, O
DHEA O
sulfate, O
LPC B-lipid
O-16:1, I-lipid
PC B-lipid
14:0, I-lipid
PE B-lipid
19:0, I-lipid
LPC B-lipid
18:2, I-lipid
PE-NMe B-lipid
36:2. I-lipid

Decline O
in O
the O
urinary O
excretion O
of O
FA B-lipid
20:4;O I-lipid
in O
RVD O
was O
suggested O
to O
reflect O
decreased O
FA O
20:4;O O
production O
by O
the O
TAL O
and O
proximal O
tubules O
that O
may O
contribute O
to O
increased O
Na_+ O
reabsorption O
in O
these O
tubular O
segments. O

As O
shown O
in O
the O
K-M O
survival O
curve, O
the O
survival O
rate O
in O
high O
level O
group O
of O
the O
3 O
selected O
serum O
metabolites O
(FA O
6:2, I-lipid
4-methylphenyl O
dodecanoate O
and O
glycerol O
tributanoate) O
together O
was O
significant O
lower O
than O
in O
those O
in O
low O
level O
group O
of O
the O
3 O
selected O
serum O
metabolites O
(Figure O
) O
(p O
<0.05). O

Trimethylsilylpropionic O
acid-d_4 O
sodium O
salt O
(TSP), O
FA B-lipid
13:0, I-lipid
chlorophenylalanine, O
lactic O
acid, O
valine, O
leucine, O
isoleucine, O
methionine, O
carnitine, O
tyrosine, O
tryptophan, O
myristic O
acid, O
margaric O
acid, O
linolenic O
acid, O
linoleic O
acid O
and O
pyroglutamic O
acid O
were O
purchased O
from O
Sigma-Aldrich O
(analytical O
grade, O
St. O
Louis, O
MO). O

We O
further O
examined O
whether O
ovarian O
cancer O
homogenates O
produce O
higher O
levels O
of O
FA B-lipid
20:4;O I-lipid
when O
incubated O
with O
AA O
as O
compared O
to O
normal O
tissue. O

For O
instance, O
linoleic O
acid O
can O
modulate O
BRCA1 O
gene O
expression O
and O
increase O
FA B-lipid
20:4;O I-lipid
and O
FA O
20:4;O O
production O
in O
BC, O
thereby O
promoting O
proliferation, O
angiogenesis O
and O
immunomodulation O
in O
tumors. O

Five-fold O
dilution O
integration O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid

FA B-lipid
20:4;O I-lipid
and O
FA O
20:4;O O
are O
products O
of O
lipoxygenase O
and O
cytochrome O
P450 O
enzymes O
and O
exert O
both O
pro O
and O
anti-inflammatory O
effects. O

To O
determine O
whether O
FA B-lipid
20:4;O I-lipid
can O
activate O
small O
GTPase O
Ras, O
HRPTEC O
cells O
were O
treated O
with O
20 O
μM O
WIT003 O
(FA O
20:4;O O
agonist) O
and O
incubated O
with O
Ras O
binding O
domain O
(RBD) O
of O
Raf1, O
to O
specifically O
isolate O
the O
active O
GTP-bound O
form O
of O
Ras. O

The O
tumor-promoting O
effects O
of O
FA B-lipid
20:4;O I-lipid
catalyzed O
by O
ω-hydroxylation O
of O
AA O
by O
the O
CYP4A/F O
enzymes O
has O
been O
documented O
in O
numerous O
studies O
(–). O

All O
definitions O
were O
obtained O
from O
the O
National O
ST B-lipid
27:1;O I-lipid
Education O
Program's O
Adult O
Treatment O
Panel O
III O
report O
. O

In O
our O
lipidomics O
analysis, O
TG B-lipid
56:4 I-lipid
was O
the O
second O
most O
significantly O
increased O
TG O
species O
with O
a O
p O
value O
of O
0.0006. O

We O
believe O
it O
is O
reasonable O
to O
consider O
the O
use O
of O
interventions O
targeting O
the O
metabolism O
of O
LPC B-lipid
O-15:1, I-lipid
PC B-lipid
O-34:5, I-lipid
and O
PC B-lipid
38:6 I-lipid
as O
a O
palliative O
treatment O
for O
patients O
with O
ascites. O

We O
identified O
some O
metabolites O
that O
were O
not O
measured O
in O
GDM O
patients O
before, O
such O
as O
n-acetylaspartic O
acid, O
2,3,4-trihydroxybutyric O
acid, O
FA B-lipid
4:0;N, I-lipid
2-oxo-4-methylvaleric O
acid, O
FA O
4:0;N, O
aminomalonic O
acid, O
1-monooleoylglycerol, O
FA B-lipid
8:0, I-lipid
mannose, O
maltose, O
threitol, O
threonic O
acid. O

Furthermore, O
western O
blotting, O
immunohistochemistry O
and O
LC–MS/MS O
analysis O
showed O
that O
the O
expression O
of O
the O
CYP4F2 O
protein O
level O
and O
the O
production O
of O
FA B-lipid
20:4;O I-lipid
was O
increased O
in O
human O
ovarian O
cancer O
samples. O

collision O
energy O
12 O
eV, O
8iPGF_3 O
351.0 O
->193.0, O
collision O
energy O
22 O
eV, O
20-COOH-LTB_4 O
365.0 O
->195.0, O
collision O
energy O
13 O
eV, O
RvD1, O
RvD2 O
375.0 O
->141.3, O
collision O
energy O
13 O
eV; O
RvE1 O
375.1 O
->141.3, O
collision O
energy O
13 O
eV; O
from O
9.0–12.5 O
min O
for O
FA B-lipid
18:2;O I-lipid
294.7 O
->170.7, O
collision O
energy O
16 O
eV; O
FA O
18:2;O O
294.7 O
->194.7, O
collision O
energy O
16 O
eV; O
FA B-lipid
20:5;O I-lipid
317.0 O
->115.0, O
collision O
energy O
17 O
eV; O
FA O
20:5;O O
317.0 O
->179.0, O
collision O
energy O
17 O
eV; O
FA O
20:5;O O
317.0 O
->219.0, O
collision O
energy O
17 O
eV, O
LTC_4 O
623.9 O
->272.0, O
collision O
energy O
14 O
eV O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->279.0, O
collision O
energy O
10 O
eV; O
8-HEPE O
317.0 O
->255.0, O
collision O
energy O
17 O
eV, O
FA O
20:5;O O
317.0 O
->259.0, O
collision O
energy O
17 O
eV; O
5-oxoETE, O
12-oxoETE O
and O
15-oxoETE O
317.0 O
->273.0, O
collision O
energy O
17 O
eV, O
FA B-lipid
20:4;O I-lipid
319.0 O
>245.0, O
collision O
energy O
10 O
eV; O
LTC_4 O
623.9 O
->272.0, O
collision O
energy O
14 O
eV; O
LTE_4 O
438.0 O
->333.0, O
collision O
energy O
13 O
eV O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->59.2, O
collision O
energy O
25 O
eV; O
EPA O
301.0 O
->203.2, O
collision O
energy O
12 O
eV; O
AA O
303.0 O
->259.3, O
collision O
energy O
11 O
eV, O
DHA O
327.1 O
->29.3, O
collision O
energy O
14 O
eV. O
Method O
B O
from O
0.0–9.8 O
min O
for O
PGE_2 O
, O
d15d12PGD_2 O
, O
PGD_2 O
, O
d15d12PGJ_2 O
, O
PGJ_2 O
315.0 O
->271.3, O
collision O
energy O
13 O
eV; O
LTB_5 O
333.0 O
->195.0, O
collision O
energy O
13 O
eV; O
LTB_4 O
335.0 O
->195.0, O
collision O
energy O
13 O
eV; O
RvE_1 O
349.1 O
->195.3, O
collision O
energy O
13 O
eV; O
HXA_3 O
, O
HXB_3 O
, O
20-COOH-AA O
335.0 O
->273.3, O
collision O
energy O
13 O
eV; O
LXA_5 O
349.0 O
->115.0, O
collision O
energy O
12 O
eV; O
20-OH-LTB_4 O
351.0 O
->195.0, O
collision O
energy O
13 O
eV; O
MaR O
359.0 O
->250.0, O
collision O
energy O
13 O
eV; O
from O
9.8–12.5 O
min O
for O
FA O
20:4;O O
318.7 O
->115.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->155.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->167.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->179.0, O
collision O
energy O
14 O
eV; O
FA O
20:4;O O
319.0 O
->218.9, O
collision O
energy O
11 O
eV; O
4-HDHA O
343.0 O
->101.0, O
collision O
energy O
10 O
eV; O
10-HDHA O
343.0 O
->181.0, O
collision O
energy O
10 O
eV; O
14-HDHA O
343.0 O
->205.0, O
collision O
energy O
10 O
eV; O
17-HDHA O
343.0 O
->245.0, O
collision O
energy O
14 O
eV, O
20-HDHA O
343.0 O
->285.0, O
collision O
energy O
10 O
eV; O
13-oxoODE O
293.0 O
->249.0, O
collision O
energy O
17 O
eV O
and O
from O
12.5–16.0 O
min O
for O
LA O
279.3 O
->59.2, O
collision O
energy O
25 O
eV; O
EPA O
301.0 O
->203.2, O
collision O
energy O
12 O
eV, O
AA O
303.0 O
->259.3, O
collision O
energy O
11 O
eV, O
DHA O
327.1 O
->229.3, O
collision O
energy O
14 O
eV. O
Stock O
solutions O
of O
the O
PUFAs, O
eicosanoids O
and O
docosanoids O
were O
prepared O
by O
dissolving O
the O
solutions O
obtained O
from O
Cayman-Chemicals O
(Estonia), O
BioMol O
International O
(Kastel-Med O
KFT, O
Budapest, O
H), O
Sigma-Aldrich O
(Budapest O
H), O
Larodan O
Lipids O
(Malmö, O
Sweden) O
and O
Dr. O
Charles O
Serhan O
(Harvard, O
USA) O
with O
methanol O
to O
yield O
a O
final O
concentration O
of O
10 O
μg/ml. O

In O
the O
present O
study, O
the O
concentration O
levels O
of O
3 O
volatile O
metabolites O
(4-heptanone, O
2-methylpyrazine O
and O
FAL B-lipid
5:0) I-lipid
in O
urine O
samples O
from O
patients O
with O
B-NHL O
were O
significantly O
higher O
compared O
with O
non-lymphoma O
subjects, O
and O
the O
concentration O
of O
1 O
of O
the O
metabolites O
(4-heptanone) O
was O
significantly O
different O
between O
early O
and O
advanced O
stages O
of O
lymphoma, O
indicating O
that O
4-heptanone O
may O
be O
a O
potentially O
useful O
biomarker O
for O
screening O
of O
B-NHL. O

(A) O
Unsaturated O
fatty O
acids O
(contain O
one O
or O
more O
C=C O
double O
bonds) O
are O
prone O
to O
lipid O
peroxidation, O
resulting O
in O
the O
formation O
of O
lipid O
aldehydes, O
acrolein O
(AL), O
malondialdehyde O
(MDA) O
and O
FAL B-lipid
9:0;O I-lipid
(HNE). O

Furthermore, O
our O
survival O
analysis O
found O
that O
2 O
SPs O
(SM O
d16:1/18:0 O
and O
SM B-lipid
36:1;O2) I-lipid
were O
significantly O
associated O
with O
diabetes O
occurrence, O
independent O
of O
age, O
sex, O
plasma O
lipid O
profile, O
and O
BMI, O
with O
HRs O
of O
about O
1.4, O
suggesting O
that O
these O
SPs O
may O
be O
used O
as O
potential O
novel O
predictors O
for O
the O
development O
of O
diabetes. O

LPC B-lipid
16:0 I-lipid
by O
itself O
increases O
on O
brain O
after O
stroke O
where O
it O
mediates O
phagocyte O
recruiting O
that O
can O
contribute O
to O
ischemic O
brain O
injury O
and O
also O
produces O
neuroinflammatory O
effects O
when O
applied O
on O
CNS. O

For O
example, O
the O
predicted O
λ O
_b:a O
 O
for O
FAL B-lipid
6:1 I-lipid
was O
111, O
therefore O
exchanges O
almost O
exclusively O
in O
the O
airways. O

The O
levels O
of O
the O
14 O
discriminative O
LMIs O
were O
higher O
in O
the O
PC O
and O
BTC O
groups O
than O
in O
the O
control, O
CRC O
and O
OVC O
groups, O
but O
only O
two O
LMIs O
discriminated O
between O
PC O
and O
BTC: O
lysophosphatidylcholine O
(LysoPC) O
(16:0) O
and O
LPC B-lipid
20:4. I-lipid

In O
the O
spontaneously O
hypertensive O
rat, O
increased O
renal O
FA B-lipid
20:4;O I-lipid
contributes O
to O
elevation O
of O
blood O
pressure, O
whereas O
in O
the O
salt-sensitive O
Dahl O
rat, O
reduced O
FA O
20:4;O O
synthesis O
also O
elevates O
blood O
pressure. O

(B) O
Formal O
Concept O
Analysis O
to O
visualize O
sorting O
of O
samples O
based O
on O
the O
relative O
abundance O
of O
PC B-lipid
39:6 I-lipid
and O
FC O
(22:3) O
in O
PCa O
(red O
squares) O
compared O
to O
control O
(black O
squares). O

no. O
860585), O
PC B-lipid
25:0 I-lipid
(cat. O

Alternatively, O
Willenberg O
et O
al O
. O
mentioned O
product O
ion O
spectra O
of O
FA B-lipid
20:4;O I-lipid
and O
FA O
20:4;O O
were O
similar O
and O
these O
two O
compounds O
must O
be O
separated O
chromatographically O
for O
their O
identification. O

Tandem O
mass O
spectrometric O
fragmentation O
fingerprints O
of O
standards O
for O
each O
of O
these O
metabolic O
classes O
were O
therefore O
generated O
including O
5S,6S-(7E,9E,11Z,14Z)-dihydroxyeicosatetraenoic O
acid O
(1), O
FA B-lipid
20:4;O I-lipid
(2) O
and O
FA O
20:4;O O
(3), O
α-tocopherol O
(4) O
γ-tocopherol O
(5), O
13-(6-hydroxy-2,7,8-trimethylchroman-2-yl)-2,6,10-trimethyltridecanoic O
acid O
(6), O
16-(4,5-dimethyl-3,6-dioxo O
cyclohexa-1,4-dienyl)-2,6,10,14-tetramethylhexadecanoic O
acid O
(7), O
6-hydroxy-2,7-dimethyl-2-(4,8,12-trimethyltridecyl)chroman-8-carbaldehyde O
(8), O
6-hydroxy-2,7-dimethyl-2-(4,8,12-trimethyltridecyl)chroman-8-carboxylic O
acid O
(9), O
calciferol O
(10), O
cholecalciferol O
(11), O
ergosterol O
(12), O
phylloquinone O
(13), O
retinol O
(14) O
and O
3β,7α-dihydroxy-5-cholestenoic O
acid O
(15) O
(Table O
). O

All O
other O
organic O
acid O
standards O
including O
lactic O
acid, O
beta-hydroxybutyric O
acid, O
alpha-ketoglutaric O
acid, O
citric O
acid, O
butyric O
acid, O
isobutyric O
acid, O
FA B-lipid
3:0, I-lipid
p-hydroxyhippuric O
acid, O
succinic O
acid, O
fumaric O
acid, O
pyruvic O
acid, O
hippuric O
acid, O
methylmalonic O
acid, O
homovanillic O
acid, O
indole-3-acetic O
acid, O
uric O
acid, O
and O
their O
isotope-labeled O
standards O
were O
purchased O
from O
Sigma-Aldrich O
(St. O
Louis, O
MO, O
USA). O

Finally, O
we O
identified O
LPC B-lipid
22:6 I-lipid
as O
a O
potential O
LAA O
biomarker. O

The O
metabolites O
were O
ChoE(18:1), O
ChoE(18:2), O
ChoE(20:4), O
PE B-lipid
34:1, I-lipid
SM B-lipid
41:1;O2, I-lipid
SM B-lipid
42:3;O2 I-lipid
and O
TG B-lipid
54:1 I-lipid
and O
the O
model O
was: O

Interestingly, O
Lemaitre O
et O
al. O
reported O
a O
complex O
relationship O
between O
several O
SMs O
(including O
SM B-lipid
36:1;O2) I-lipid
and O
insulin O
sensitivity O
that O
was O
dependent O
upon O
BMI. O

CYP O
monooxygenases O
are O
expressed O
in O
the O
renal O
vasculature O
and O
nephron, O
generating O
primarily O
FA B-lipid
20:4;O I-lipid
(20-HETE) O
by O
ω O
- O
and O
ω O
-1 O
hydroxylases O
and O
5,6-, O
8,9-, O
11,12-, O
and O
14,15-epoxyeicosatrienoic O
acids O
(EETs) O
by O
epoxygenases. O

It O
was O
also O
challenging O
to O
compare O
the O
TLC/GC-FID O
lipid O
results O
with O
the O
GC-MS O
results O
as O
the O
two O
methods O
only O
identified O
and O
quantified O
8 O
metabolites O
in O
common O
(arachidonic O
acid, O
FA B-lipid
20:0, I-lipid
linoleic O
acid, O
oleic O
acid, O
palmitelaidic O
acid, O
palmitic O
acid, O
stearic O
acid O
and O
tetradecanoic O
acid). O

ST B-lipid
27:1;O I-lipid
is O
metabolised O
in O
the O
CNS O
in O
astrocytes O
through O
cytochrome O
P450 O
(CYP) O
27A1 O
catalysed O
oxidation O
to O
(25R)26-HC O
and O
subsequently O
to O
3β-HCA O
and O
then O
on O
to O
3β,7α-diHCA O
and O
7αH,3O-CA O
by O
the O
consecutive O
action O
of O
CYP7B1 O
and O
hydroxysteroid O
dehydrogenase O
(HSD) O
3B7 O
enzymes O
(Fig. O
). O

Abbreviations: O
MSA: O
multiple O
system O
atrophy; O
PSP: O
progressive O
supranuclear O
palsy; O
AUC: O
area O
under O
the O
curve; O
FA: O
fatty O
acid; O
LPC B-lipid
16:0: I-lipid
lysophosphatidylcholine O
(16:0); O
DHEAS: O
dehydroisoandrosterone O
3-sulfate; O
SDMA: O
symmetric O
dimethylarginine O
fatty O
acid; O
AC: O
acylcarnitine; O
Met: O
methionine. O

These O
7 O
metabolites O
were O
acetone, O
2-butanone, O
4-heptanone, O
dimethyl O
disulfide, O
furan, O
FAL B-lipid
5:0 I-lipid
and O
2-methylpyrazine. O

ST B-lipid
27:1;O I-lipid
levels O
are O
largely O
controlled O
by O
the O
liver, O
which O
is O
the O
major O
source O
of O
cholesterol O
and O
LDL O
via O
very O
low-density O
lipoprotein O
(VLDL) O
production, O
and O
also O
the O
major O
site O
of O
LDL O
catabolism. O

Furthermore, O
FA B-lipid
4:0;O I-lipid
(α-hydroxybutyrate; O
AHBA) O
shows O
the O
lowest O
p O
-value O
of O
all O
metabolites O
between O
control O
and O
GDM O
and O
therefore O
is O
one O
of O
the O
strongest O
metabolic O
alterations O
(Supplementary O
Figure O
). O

At O
pH O
2, O
8 O
VOCs O
stood O
out, O
namely, O
cyclohexanone O
(Fig. O
), O
4-methylheptan-2-one, O
2-methylpentane-1,3-diol, O
4-methylbenzaldehyde O
(Fig. O
), O
1-(3,5-dimethylfuran-2-yl) O
ethanone, O
methyl O
benzoate, O
FA B-lipid
9:0 I-lipid
and O
FA B-lipid
10:0 I-lipid
(Fig. O
) O
as O
they O
revealed O
to O
be O
important O
for O
the O
separation O
between O
all O
PCa O
cell O
lines O
and O
normal O
cell O
line O
(Table O
). O

ST B-lipid
27:1;O I-lipid
concentrations O
in O
CSF O
were O
not O
changed O
except O
for O
patients O
diagnosed O
with O
amyotrophic O
lateral O
sclerosis O
(P O
 < 0.01) O
or O
pathogen-based O
infections O
of O
the O
CNS O
(P O
 < 0.05) O
where O
they O
were O
elevated. O

The O
25 O
VOMs O
m-cresol, O
3-heptanone, O
benzene, O
4-methyl-2-heptanone, O
acetone, O
1-propanol, O
FAL B-lipid
9:0, I-lipid
4-tert-butylphenol, O
phenol, O
3-methyl-2-heptanone, O
dimethyltrisulfide, O
2-hexanone, O
FA B-lipid
2:0, I-lipid
furan, O
FAL B-lipid
6:0, I-lipid
2-methyl-5-(methylthio) O
furan, O
FAL B-lipid
7:0, I-lipid
dimethyldisulfide, O
2-methylthiophene, O
tetrahydro-2,2-dimethyl-5-(1-methyl-1-propenyl)furan, O
2-methylbutyric O
acid, O
styrene, O
2-ethylfuran, O
ethylbenzene O
and O
thiophene O
were O
significantly O
increased O
in O
the O
urine O
of O
patients O
with O
malignant O
neoplasia. O

FA B-lipid
4:0;N I-lipid
is O
a O
key O
intermediate O
in O
the O
biosynthesis O
of O
ophthalmic O
acid, O
which O
was O
used O
as O
a O
biomarker O
in O
oxidative O
stress. O

In O
our O
analysis, O
FA B-lipid
4:0;O I-lipid
(aka O
beta-hydroxybutyrate O
(βOHB)) O
– O
hepatic O
ketone O
body O
– O
displayed O
a O
negative O
association O
with O
HOMA-IR. O

Significantly O
decreased O
levels O
of O
LPC B-lipid
18:1 I-lipid
and O
LPC B-lipid
18:2 I-lipid
have O
been O
observed O
in O
obese O
children. O

We O
performed O
MS_3 O
CID O
of O
all O
major O
fragments O
within O
the O
m O
/z O
range O
600–800 O
formed O
from O
MS_2 O
CID O
of O
the O
bicarbonate O
adduct O
of O
PC B-lipid
34:1. I-lipid

It O
is O
well O
known O
that O
FA B-lipid
18:1;O2 I-lipid
is O
produced O
in O
humans O
from O
linoleic O
acid, O
via O
its O
oxidation O
(by O
P450 O
monoxygenase) O
to O
the O
protoxin O
FA B-lipid
18:2;O I-lipid
(isoleukotoxin), O
followed O
by O
conversion O
to O
FA O
18:1;O2 O
via O
the O
FA O
18:2;O O
by O
sEH. O

Two O
LMIs O
(496.3 m O
/z O
, O
retention O
time O
(RT) O
of O
18.9 min O
a O
and O
544.3 m O
/z O
, O
RT O
of O
18.3 min O
b O
were O
identified O
as O
LysoPC(16,0) O
and O
LPC B-lipid
20:4 I-lipid
according O
to O
the O
tandem O
mass O
spectrometry O
(MS/MS) O
patterns O
of O
serum O
samples O
of O
BTC O
patients O
Amounts O
of O
LPC B-lipid
16:0 I-lipid
and O
LPC O
20:4 O
in O
the O
serum O
of O
PC O
and O
BTC O
patients. O

Also, O
the O
fatty O
acid O
composition O
of O
these O
two O
species O
is O
different O
(primary O
constituent O
of O
PC B-lipid
O-38:6 I-lipid
is O
PC B-lipid
38:6 I-lipid
while O
that O
for O
PC O
38:6b O
is O
PC O
38:6). O

Low O
plasma O
levels O
of O
LPC B-lipid
16:0 I-lipid
arose O
as O
a O
potential O
predictor O
of O
recurrence, O
especially O
in O
patients O
with O
early O
SR. O

As O
shown O
in O
, O
four O
lysophosphatidylcholines O
(LysoPCs) O
(LPC O
14:0, I-lipid
LPC B-lipid
16:1, I-lipid
LPC B-lipid
20:0, I-lipid
and O
LPC B-lipid
O-18:2) I-lipid
were O
observed O
significantly O
lower O
in O
the O
serum O
of O
CRC O
patients O
compared O
with O
healthy O
controls. O

Equally O
good O
matching O
was O
observed O
for O
retention O
times O
of O
authentic O
standard O
of O
SM B-lipid
36:2;O2 I-lipid
and O
the O
observed O
SM O
36:2;O2 O
(not O
shown). O

LPC B-lipid
17:0, I-lipid
the O
only O
odd O
chain O
LPC O
detected O
in O
our O
study, O
showed O
different O
behavior O
than O
other O
LPCs, O
with O
non-significant O
correlation O
with O
the O
disease O
and O
negative O
correlation O
to O
the O
parasitaemia O
values. O

FA B-lipid
20:4;O I-lipid
in O
veterans O
with O
GWI O
was O
by O
decreased O
by O
63% O
(Z O
= O
-0.84, O
), O
and O
contributed O
4% O
of O
the O
metabolic O
impact O
(, O
VIP O
= O
2.2). O

Monohydroxy O
oxylipins O
were O
also O
assessed, O
and O
while O
levels O
of O
the O
arachidonic O
acid O
(AA)-derived O
COX-metabolite O
FA B-lipid
20:4;O I-lipid
were O
significantly O
lower O
in O
ASA-treated O
patients O
compared O
with O
untreated O
subjects, O
FA O
20:4;O O
as O
well O
as O
EPA-derived O
HEPEs, O
FA B-lipid
20:5;O I-lipid
and O
FA O
20:5;O, O
did O
not O
show O
differences O
in O
tissue O
levels O
between O
patients O
treated O
with O
ASA O
and O
those O
without O
ASA. O

Specifically, O
S1P O
and O
LPA B-lipid
18:2 I-lipid
each O
had O
a O
good O
predictability O
of O
disease O
status O
(AUC O
> O
0.80; O
). O

Cluster O
2, O
comprised O
predominantly O
of O
C18-derived O
esterified O
diols O
(FA O
18:1;O2, I-lipid
9,10- O
DiHOME, O
FA B-lipid
18:2;O2, I-lipid
FA O
18:2;O2), O
negatively O
correlated O
with O
VCAM-1 O
expression. O

The O
branched O
fatty O
acid O
3-methyl-2-oxopentanoic O
acid O
and O
28.6% O
(2/7) O
of O
saturated O
fatty O
acids O
(palmitic O
acid O
and O
stearic O
acid) O
were O
increased, O
while O
71.4% O
(5/7) O
of O
saturated O
fatty O
acids O
(margaric O
acid, O
arachidic O
acid, O
FA B-lipid
22:5 I-lipid
(DPA), O
FA B-lipid
16:0, I-lipid
FA B-lipid
3:1;O2 I-lipid
(methyl, O
ethyl O
ester), O
FA O
3:1;O2 O
(methyl, O
ethyl O
ester)) O
were O
decreased. O

However, O
there O
is O
also O
co-elution O
of O
neutral O
and O
lipid O
compounds; O
testosterone-d_2 O
co-eluted O
with O
17:0 O
Cer, O
and O
PC B-lipid
34:1 I-lipid
co-eluted O
with O
an O
unknown O
compound O
with O
a O
similar O
m/ O

Of O
interest O
they O
identified O
increases O
in O
a O
number O
of O
lysophosphatidylcholine O
lipid O
species O
(specifically O
LPC O
10:0 O
and O
LPC B-lipid
20:0) I-lipid
with O
ART O
initiation O
which O
was O
also O
seen O
in O
all O
arms O
of O
our O
study, O
with O
no O
difference O
across O
arms, O
suggesting O
that O
these O
changes O
are O
not O
specific O
to O
an O
ARV O
class O
and O
thus O
may O
be O
secondary O
to O
changes O
in O
HIV O
driven O
inflammation O
and O
innate O
immune O
function. O

The O
levels O
of O
PE B-lipid
32:1, I-lipid
PE B-lipid
34:3, I-lipid
PE B-lipid
34:2, I-lipid
PE B-lipid
34:0, I-lipid
PE B-lipid
35:2, I-lipid
PE B-lipid
35:1, I-lipid
PE O
35:1, O
PE B-lipid
36:5, I-lipid
PE B-lipid
36:1, I-lipid
PE B-lipid
38:5, I-lipid
PE B-lipid
38:3, I-lipid
PC B-lipid
33:1, I-lipid
PC B-lipid
36:6, I-lipid
and O
PC B-lipid
38:1 I-lipid
in O
early-stage O
NSCLC O
were O
significantly O
increased O
compared O
with O
HC O
(p<0.05). O

Our O
findings O
on O
the O
increased O
concentration O
of O
FA B-lipid
20:4;O, I-lipid
suggesting O
increased O
activity O
of O
CYP O
enzyme, O
would O
support O
promotion O
of O
cellular O
detoxification O
mechanisms O
through O
specific O
modulation O
of O
the O
arachidonic O
acid O
metabolic O
cascade O
in O
centenarians. O

They O
observed O
that O
a O
few O
lipids O
like O
LysoPC O
(16:0), O
LPA B-lipid
16:0 I-lipid
and O
LPA O
16:0 O
were O
aberrantly O
expressed O
in O
CTCL O
plasma O
in O
positive O
and O
negative O
modes. O

MS/MS O
analysis O
on O
features O
810.597 O
at O
RT O
25.11 O
(peak O
#3) O
and O
RT O
25.58 O
(peak O
#4) O
identified O
two O
PC B-lipid
38:4 I-lipid
with O
a O
similar O
MS/MS O
signal O
intensity O
pattern O
for O
the O
two O
fragments O
corresponding O
to O
their O
fatty O
acyl O
side O
chain: O
higher O
at O
m/z O
303.23 O
for O
C20:4, O
most O
likely O
on O
sn-2 O
position, O
and O
lower O
at O
m/z O
283.26 O
for O
C18:0. O

We O
did, O
however, O
measure O
increased O
LPC O
species O
enriched O
for O
SaFAs, O
including O
LPC B-lipid
17:0 I-lipid
and O
LPC B-lipid
20:0, I-lipid
whereas O
the O
proportional O
amount O
of O
LPC B-lipid
18:2 I-lipid
was O
significantly O
decreased. O

According O
to O
this O
cutoff O
value, O
it O
was O
observed O
that O
61 O
out O
of O
68 O
samples O
(89.7%) O
could O
be O
accurately O
predicted O
in O
the O
discovery O
set O
(, O
left), O
which O
indicated O
that O
LG O
BC O
and O
HG O
BC O
patients O
could O
be O
well-stratified O
with O
high O
accuracy O
by O
using O
the O
combination O
of O
inosine, O
AFMK O
and O
LPS B-lipid
O-18:0. I-lipid

Furthermore, O
IBS O
patients O
with O
high O
acetic O
acid O
or O
FA B-lipid
3:0 I-lipid
levels O
presented O
more O
severe O
symptoms, O
impaired O
quality O
of O
life O
and O
negative O
emotions. O

Only O
a O
few O
correlations O
were O
found O
for O
PC B-lipid
28:1, I-lipid
PC B-lipid
30:2, I-lipid
PC B-lipid
40:1, I-lipid
PC B-lipid
42:6, I-lipid
GPCe O
38:6 O
and O
SM B-lipid
22:3;O2 I-lipid
within O
the O
respective O
lipid O
classes. O

The O
nuclear O
and O
mitochondrial O
fractions O
were O
removed O
by O
centrifugation O
and O
1 O
mg/ml O
of O
the O
lysate O
was O
incubated O
for O
1 O
h O
at O
37°C O
in O
the O
presence O
of O
100% O
O_2 O
with O
exogenous O
AA O
(40 O
μM), O
1 O
mM O
NADPH O
and O
2 O
μM O
indomethacin O
(to O
prevent O
metabolism O
of O
FA B-lipid
20:4;O I-lipid
by O
COX). O

No O
statistically O
significant O
differences O
between O
males O
and O
females, O
neither O
for O
the O
AML O
cases O
nor O
the O
controls, O
were O
found O
for O
the O
following O
plasma O
eicosanoids: O
DHGLA O
[20:3(8Z O
,11Z O
,14Z O
)], O
arachidonic O
acid O
[20:4(5Z O
, O
8Z O
,11Z O
,14Z O
)], O
EPA O
[20:5(5Z O
, O
8Z O
,11Z O
,14Z O
,17Z O
)], O
FA B-lipid
20:3;O2, I-lipid
11-dehydro-TxB2, O
PGE2/8-isoPGE2, O
12-HEPE, O
11β-PGE2, O
15-keto-PGF2α, O
15-keto-PGE2, O
8-iso-15-keto-PGF2α, O
PGF1α, O
and O
PGF2α. O

Abbreviations: O
FA B-lipid
20:4;O, I-lipid
FA B-lipid
20:3;O; I-lipid
α-KG, O
α-ketoglutarate; O
ACC, O
acetyl-CoA O
carboxylase; O
ACLY, O
acetyl-CoA O
lyase; O
cPA, O
cyclic O
phosphatidic O
acid; O
CPT1, O
carnitine O
palmitoyltransferase O
I; O
DG, O
diacylglycerides; O
FA, O
fatty O
acid; O
FA-CoA, O
fatty O
acyl-CoA; O
FA-carnitine, O
fatty O
acyl-carnitine; O
FASN, O
fatty O
acid O
synthase; O
GA3P, O
glyceraldehyde O
3-phosphate; O
G3P, O
glycerol O
3-phosphate; O
LPA, O
lysophosphatidic O
acid; O
LPC, O
lysophosphatidylcholine; O
MAGL, O
monoacylglycerol O
lipase; O
MG, O
monoacyl O
glycerides; O
PA, O
phosphatidic O
acid; O
PC, O
phosphatidylcholine; O
PLA2, O
phospholipase O
A2; O
PLC, O
phospholipase O
C; O
PLD, O
phospholipase O
D; O
SCD, O
stearoyl-CoA O
desaturase; O
SM, O
sphingomyelin; O
SMS, O
sphingomyelin O
synthase; O
TCA O
cycle, O
tricarboxylic O
acid O
cycle; O
TG, O
triacylglycerides. O

(A) O
ROC O
curves O
based O
on O
the O
random O
forest O
model O
with O
leave-one-out O
cross-validation O
for O
prediction O
with O
31 O
candidate O
lipid O
biomarkers; O
(B) O
The O
inclusion O
of O
LPG B-lipid
20:5 I-lipid
level O
to O
related O
prognostic O
clinical O
characteristics O
including O
serum O
CA-125 O
level, O
omentum O
metastasis, O
FIGO O
stage, O
histology O
differentiation O
grade O
and O
lymph O
node O
metastasis O
to O
receiver O
operating O
characteristic O
curve O
increase O
the O
predictive O
power O
of O
EOC O
recurrence O
(area: O
clinical O
characteristics: O
0.739, O
P O
< O
0.01(blue O
line); O
LPG O
20:5: O
0.736, O
P O
< O
0.001 O
(red O
line); O
clinical O
characteristics O
+ O
LPG O
20:5: O
0.875, O
P O
< O
0.001(green O
line)); O
(C) O
Kaplan–Meier O
curve O
comparing O
EOC O
recurrence O
with O
lower O
LPG O
20:5 O
values O
(blue O
line) O
and O
higher O
LPG O
20:5 O
values O
(green O
line). O

The O
white O
bar O
corresponds O
to O
the O
lipids O
identified O
in O
both O
fractionated O
and O
non-fractionated O
full O
extract, O
but O
the O
level O
of O
identification O
was O
improved O
in O
the O
fractionated O
yeast O
(molecular O
species O
level, O
e.g., O
PC B-lipid
32:1 I-lipid
instead O
of O
lipid O
species O
level, O
e.g., O
PC O
32:1). O

According O
with O
us, O
recent O
study O
also O
showed O
that O
FA B-lipid
20:4;O I-lipid
was O
associated O
with O
endothelial O
cell O
proinflammatory O
actions O
that O
promote O
atherosclerosis O
and O
vascular O
remodeling. O

Interestingly, O
PC B-lipid
32:0, I-lipid
which O
could O
correspond O
to O
PC O
32:0, O
was O
recently O
reported O
as O
a O
potential O
signature O
of O
progressive O
forms O
of O
fatty O
liver O
disease. O

LPC B-lipid
18:3, I-lipid
SM B-lipid
34:1;O2, I-lipid
and O
Cer B-lipid
42:2;O2 I-lipid
were O
retained O
in O
the O
final O
TAG O
model. O

Levels O
of O
capric O
acid, O
cis-9-palmitoleic O
acid, O
FA B-lipid
12:0, I-lipid
oleic O
acid O
and O
palmitic O
acid O
were O
decreased O
in O
children O
and O
adolescents O
with O
MDD O
who O
were O
drug-naive O
compared O
with O
healthy O
controls. O

In O
our O
data, O
lower O
levels O
of O
PC B-lipid
36:4, I-lipid
PE B-lipid
O-36:5, I-lipid
and O
PC B-lipid
O-36:5 I-lipid
and O
in O
the O
CRC O
tissue O
samples O
were O
observed, O
and O
these O
results O
may O
exhibit O
the O
results O
of O
releasing O
FA O
20:4(n-6) O
from O
PC O
36:4 O
and O
PE O
O-36:5 O
and O
the O
results O
of O
releasing O
FA20:5(n-3) O
from O
PC O
O-36:5. O

Representative O
product O
ion O
spectrum O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
proposed O
structures O
of O
main O
product O
ions O
of O
Cer O
22:0;O2, O
Cer B-lipid
24:0;O2, I-lipid
[_2 O
H_4 O
]Cer O
22:0;O2 O
and O
[_2 O
H_4 O
]Cer O
24:0;O2 O

Four O
hydroxy-epoxy-octadecenoic O
acids O
[FA O
18:1;O2 I-lipid
(9-H-12-E-LA), O
FA O
18:1;O2 O
(11-H-12-E-LA), O
FA O
18:1;O2 O
(11-H-9-E-LA), O
FA O
18:1;O2 O
(13-H-9-E-LA)] O
and O
three O
keto-epoxy-octadecenoic O
acids O
[FA O
18:2;O2 I-lipid
(11-K-12-E-LA), O
FA O
18:2;O2 O
(11-K-9-E-LA), O
FA O
18:2;O2 O
(13-K-9-E-LA)] O
employed O
in O
this O
study O
were O
custom-synthesized O
by O
Cayman O
Chemical O
with O
purities O
of O
> O
95%. O

The O
samples O
were O
extracted O
using O
a O
single O
extraction O
with O
400 O
µl O
of O
methanol, O
containing O
the O
recovery O
standards: O
FA B-lipid
13:0, I-lipid
fluorophenylglycine, O
chlorophenylalanine O
and O
d6-cholesterol. O

However, O
two O
LMIs O
(496.3 O
m/z O
at O
an O
RT O
of O
18.9 min O
and O
544.3 O
m O
/z O
at O
an O
RT O
of O
18.3 min), O
lysophosphatidylcholine O
(LysoPC) O
(16:0) O
and O
LPC B-lipid
20:4, I-lipid
identified O
according O
to O
their O
MS/MS O
patterns O
in O
the O
analyses O
of O
the O
sera O
of O
BTC O
patients, O
could O
discriminate O
between O
PC O
and O
BTC O
(Figs. O
and O
, O
Table O
). O

ST B-lipid
27:1;O I-lipid
concentration O
is O
in O
microgram O
per O
milliliter O
other O
analyte O
concentrations O
are O
in O
nanogram O
per O
milliliter. O

TG B-lipid
48:2 I-lipid
which O
was O
detected O
in O
19/24 O
samples O
out O
of O
which O
ten O
were O
in O
the O
second O
batch, O
was O
on O
the O
other O
hand O
detected O
in O
the O
first O
and O
immediately O
repeated O
injections, O
but O
not O
detected O
after O
prolonged O
storage. O

Through O
the O
comparison O
between O
these O
metabolites O
and O
pathways O
and O
the O
predicted O
metabolites O
and O
pathways, O
we O
found O
that O
phosphatidic O
acid, O
inosine O
and O
SE B-lipid
27:1/18:0 I-lipid
were O
their O
common O
metabolites. O

We O
manually O
selected O
a O
combination O
of O
three O
metabolites O
namely O
FA B-lipid
15:0, I-lipid
1-linoleoylglycerophosphocholine O
and O
linoleoyl O
carnitine O
to O
create O
a O
biomarker O
model O
to O
distinguish O
between O
these O
two O
groups O
using O
RF O
(random O
forest) O
algorithm. O

The O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
were O
determined O
to O
be O
stable O
for O
38 O
days O
at O
−80 O
°C. O

shows O
down-regulation O
of O
fatty O
acid O
of O
tetracosahexaenoic O
acid O
and O
FA B-lipid
20:0;O I-lipid
in O
HCC O
cases O
compared O
to O
cirrhotic O
controls. O

FA B-lipid
16:0 I-lipid
has O
a O
better O
discriminating O
ability O
in O
comparison O
to O
the O
pretherapeutic O
tumor O
marker O
CA O
19-9 O
suggesting O
that, O
the O
joint O
evaluation O
of O
both O
pretherapeutic O
tumor O
markers O
CA19-9 O
and O
palmitic O
acid O
levels O
should O
be O
recommended O
in O
order O
to O
significantly O
reduce O
the O
probability O
to O
detect O
false O
positives O
and O
it O
could O
be O
used O
to O
improve O
the O
prognostic O
prediction O
in O
patients O
with O
pancreatic O
cancer. O

Five O
key O
metabolites, O
including O
sucrose, O
cellobiose, O
hypoxanthine, O
ketoglutaric O
acid, O
and O
FA B-lipid
6:0, I-lipid
were O
selected O
as O
markers O
for O
the O
ATG O
by O
using O
a O
VIP O
threshold O
of O
1.5. O

The O
largest O
changes O
were O
increases O
in O
saturated O
and O
monounsaturated O
PA O
species; O
for O
example, O
PA B-lipid
32:0 I-lipid
increased O
with O
time O
after O
infection, O
exhibiting O
an O
approximately O
fourfold O
increase O
relative O
to O
mock-infected O
cells O
at O
96 O
hpi O
(P O
= O
0.013; O
). O

TG B-lipid
54:5 I-lipid
therefore O
is O
an O
exception O
of O
a O
decreasing O
serum O
TAG O
with O
more O
than O
52 O
carbons. O

ST B-lipid
27:1;O I-lipid
in O
HDL O
particles O
appeared O
most O
unassociated, O
in O
contrast O
to O
previous O
MVPA O
measures O
(current O
and O
longer O
term). O

Box-whisker O
plots O
of O
the O
concentrations O
of O
(A) O
4-heptanone, O
(B) O
2-methylpyrazine, O
(C) O
FAL B-lipid
5:0, I-lipid
(D) O
2,6-dimethyl-7-octen-2-ol O
and O
(E) O
FA B-lipid
10:0. I-lipid

The O
levels O
of O
PA, O
D-Maltose, O
and O
PG B-lipid
25:0 I-lipid
were O
highest O
in O
BT O
group, O
followed O
by O
PP O
group, O
and O
finally O
GP O
group. O

Alanine O
and O
FA B-lipid
4:0;O I-lipid
also O
correlated O
to O
these O
three O
clinical O
measures, O
but O
the O
relation O
to O
glucose O
had O
a O
high O
q-value. O

 ), O
the O
plasma O
concentrations O
of O
Lyso O
PE B-lipid
18:3, I-lipid
Lyso O
PE B-lipid
20:4, I-lipid
Lyso O
PE B-lipid
22:1 I-lipid
showed O
a O
strong O
positive O
correlation O
with O
Glomerular O
Filtration O
Rate O
(eGFR), O
as O
were O
a O
number O
of O
other O
metabolites. O

Proportional O
amounts O
of O
LPC B-lipid
16:0 I-lipid
were O
positively O
associated O
with O
serum O
levels O
of O
ICAM1, O
and O
LPC B-lipid
18:2 I-lipid
was O
negatively O
associated O
with O
ICAM1. O

Twenty-one O
of O
the O
67 O
metabolites O
between O
healthy O
and O
hepatic O
were O
unique, O
including O
FA B-lipid
4:0;O, I-lipid
2-ketoisocaproic O
acid, O
α-ketoglutarate, O
glycerol-alpha-phosphate, O
oxamic O
acid, O
urea, O
and O
uridine. O

There O
is O
no O
obvious O
trend O
in O
the O
changes O
of O
the O
Δ9/Δ11 O
isomers O
and O
neither O
do O
the O
changes O
correlate O
with O
relative O
isomeric O
composition O
in O
free O
FA B-lipid
18:1 I-lipid
(I O
_Δ9 O
/I O
_Δ11 O
 = 10.5 ± O

In O
the O
current O
work, O
a O
semi-quantitative O
analysis O
of O
105 O
metabolites O
reveals O
significant O
differences O
in O
the O
faecal O
composition O
of O
cancer O
samples O
in O
the O
following O
lipids: O
PC B-lipid
32:0, I-lipid
PC B-lipid
32:1, I-lipid
PC B-lipid
O-32:0, I-lipid
PE B-lipid
34:1, I-lipid
PE B-lipid
34:2, I-lipid
SM B-lipid
34:1;O2, I-lipid
SM B-lipid
41:1;O2, I-lipid
SM B-lipid
42:3;O2 I-lipid
+ O
SM B-lipid
42:1;O2, I-lipid
SM O
42:1;O2, O
Cer B-lipid
34:1;O2, I-lipid
Cer B-lipid
42:2;O2 I-lipid
+ O
Cer O
42:2;O2, O
Cer B-lipid
42:1;O2, I-lipid
SM O
42:3;O2, O
ChoE(16:0), O
ChoE(18:1), O
ChoE(18:2), O
ChoE(20:4), O
TG B-lipid
54:1. I-lipid

By O
UPLC-MS, O
we O
identified O
2 O
metabolites O
(with O
an O
LoA O
≤ O
3) O
that O
were O
higher O
in O
PRP O
compared O
with O
PFP O
samples: O
PE B-lipid
36:2 I-lipid
and O
PC B-lipid
O-36:5. I-lipid

α–KB O
is O
produced O
by O
amino O
acid O
catabolism O
(threonine O
and O
methionine) O
and O
glutathione O
anabolism O
(cysteine O
formation O
pathway) O
and O
is O
metabolized O
to O
CoA B-lipid
3:0 I-lipid
and O
carbon O
dioxide O
. O

As O
shown O
in O
(Methanol O
precipitation) O
and O
1B O
(Methanol-ethanol O
precipitation), O
while O
most O
compounds O
were O
recovered O
and O
resolved O
using O
RPC, O
cholesterol O
and O
TG B-lipid
52:4 I-lipid
were O
not O
seen O
when O
either O
precipitation O
method O
was O
used. O
also O
includes O
data O
resulting O
from O
MTBE O
extraction O
and O
MTBE:SPE O
extraction, O
as O
discussed O
in O
detail O
later. O

To O
evaluate O
the O
recoveries O
of O
the O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
from O
human O
plasma O
and O
matrix O
(5% O
BSA), O
signals O
of O
[_2 O
H_4 O
]Cer O
22:0;O2 O
and O
[_2 O
H_4 O
]Cer O
24:0;O2from O
pre-extraction O
spiked O
samples O
to O
those O
post-extraction O
spiked O
samples O
were O
compared. O

LPC B-lipid
18:1 I-lipid
in O
HCC O
plasma O
showed O
a O
statistically O
significant O
(P<0.05) O
lower O
plasma O
concentration O
than O
in O
HV O
plasma O
was O
determined O
in O
this O
quantitative O
assay O
and O
also O
a O
statistically O
significant O
(P<0.05) O
downregulation O
in O
HCC O
relative O
to O
LC. O

LC-PB–MS/MS O
of O
e O
PE B-lipid
39:4 I-lipid
(RT: O
5.2 min, O
m/ O

Adjusted O
OR O
(95% O
CI) O
of O
MI, O
IS, O
and O
ICH O
for O
Lipoprotein O
Particle O
Concentration, O
ST B-lipid
27:1;O, I-lipid
and O
Triglycerides O
as O
Measured O
by O
Nuclear Magnetic O
Resonance O
Spectroscopy O
Estimates O
are O
odds O
ratios O
(ORs) O
per O
1-SD O
higher O
metabolic O
marker. O

This O
occurred O
alongside O
an O
increased O
TG B-lipid
52:4 I-lipid
(CHEBI: O
84660) O
and O
in O
the O
most O
abundant O
non-esterified O
fatty O
acids O
within O
adipose O
tissue. O

The O
most O
abundant O
hydroxy O
PUFA O
in O
human O
colorectal O
tissue O
samples O
was O
the O
linoleic O
acid O
(LA)-derived O
metabolite, O
FA B-lipid
18:2;O. I-lipid

We O
are O
also O
able O
to O
detect O
FA B-lipid
9:1;O I-lipid
(HNA)-MA, O
FA O
9:1;O O
lactone O
(HNAL)-MA, O
and O
FA B-lipid
9:2;O I-lipid
(ONA)-MA O
with O
this O
method. O

Three O
metabolites O
were O
identified O
that O
contributed O
to O
the O
group O
separation O
in O
both O
studies: O
FA B-lipid
4:0;O2, I-lipid
FA B-lipid
22:5, I-lipid
and O
uric O
acid. O

LPCs O
enriched O
for O
the O
SaFA O
margaric O
acid O
(17:0) O
were O
positively O
associated O
with O
the O
proportion O
of O
patrolling O
monocytes, O
and O
LPC B-lipid
20:0 I-lipid
was O
positively O
associated O
with O
surface O
expression O
of O
SR-A O
on O
patrolling O
monocytes O
and O
CD36 O
on O
inflammatory O
monocytes. O

These O
include O
PC B-lipid
34:1, I-lipid
PC B-lipid
32:1 I-lipid
(data O
are O
provided O
in O
Fig. O

Furthermore, O
for O
coeluting O
isomers O
FA B-lipid
18:2;O I-lipid
and O
FA O
18:2;O, O
and O
partially O
resolved O
isomers O
9-EpOME O
and O
13-EpOME, O
FA O
18:2;O O
and O
9-EpOME O
were O
each O
found O
to O
produce O
a O
very O
minor O
peak O
at O
m/z O
195, O
forming O
an O
MRM O
transition O
295 O
> O
195, O
corresponding O
to O
less O
than O
1% O
of O
the O
response O
at O
the O
same O
concentration O
level O
for O
FA O
18:2;O O
and O
13-EpOME. O

The O
timing O
and O
total O
volume O
were O
recorded, O
and O
the O
samples O
(2 O
mL) O
of O
urine O
were O
stored O
at O
−80°C O
for O
the O
assay O
of O
derivates O
of O
AA O
by O
CYP O
metabolism O
after O
the O
addition O
of O
deuterated O
FA B-lipid
20:4;O I-lipid
(Cayman O
Chemical O
Co), O
DHET, O
FA O
20:4;O, O
FA O
20:4;O, O
and O
FA O
20:4;O O
(Biomol) O
as O
internal O
standards. O

The O
significant O
alterations O
in O
the O
levels O
of O
FA B-lipid
10:0 I-lipid
in O
the O
PCa O
cells O
study O
is O
in O
concordance O
with O
previously O
reported O
in O
serum O
of O
PCa O
patients. O

The O
most O
altered O
metabolite O
was O
Cer B-lipid
42:3;O2, I-lipid
and O
all O
metabolites O
were O
higher O
in O
the O
case O
group, O
except O
for O
two O
of O
them, O
Cer B-lipid
34:1;O2 I-lipid
and O
TG B-lipid
54:1, I-lipid
which O
were O
lower O
than O
the O
control O
group O
(A). O

FA B-lipid
16:0. I-lipid

Similarly, O
a O
positive O
correlation O
was O
observed O
between O
plasma O
FA B-lipid
20:4;O I-lipid
and O
plasma O
concentration O
of O
homocysteine O
(r O
_s O
=0.503; O
P O
=0.005) O
and O
creatinine O
(r O
_s O
=0.460; O
P O
<0.02). O

Among O
the O
proinflammatory O
endothelial O
cell O
changes O
that O
occur O
in O
response O
to O
FA B-lipid
20:4;O I-lipid
are O
increased O
adhesion O
molecule O
expression O
and O
cytokine O
release. O

Partition O
analysis O
of O
the O
relative O
abundance O
values O
highlighted O
two O
lipids, O
FA B-lipid
22:3 I-lipid
and O
PC B-lipid
39:6 I-lipid
which O
can O
classify O
samples O
with O
higher O
specificity O
(Fisher O
test O
with O
p O
-value O
1.612e-06). O

Lipids O
lower O
in O
overweight/obesity O
included O
PC(O), O
PC(P), O
LPC(O‐24:2), O
and O
LPE B-lipid
16:0. I-lipid

Among O
subjects O
aged O
over O
75 O
years, O
females O
also O
had O
higher O
levels O
of O
DHA–containing O
phospholipids O
including O
PE B-lipid
40:6 I-lipid
and O
PC B-lipid
40:6 I-lipid
in O
positive O
mode, O
and O
PE B-lipid
40:7, I-lipid
and O
PE B-lipid
38:6 I-lipid
in O
negative O
mode, O
with O
PI B-lipid
38:6 I-lipid
trending O
higher O
but O
not O
reaching O
significance O
(, O
p O
= O
0.06). O

We O
first O
extracted O
the O
ion O
profile O
in O
the O
range O
10.06-10.26 min O
and O
then O
obtained O
the O
max O
value O
of O
that O
profile O
as O
peak O
maxima O
for O
TG B-lipid
58:8 I-lipid

The O
elevated O
plasma O
concentrations O
of O
FA B-lipid
20:4;O I-lipid
in O
RVD O
occurred O
with O
decreased O
urinary O
excretion O
of O
FA O
20:4;O O
and O
probably O
reflects O
the O
multiple O
pathways O
for O
disposition O
of O
FA O
20:4;O, O
namely, O
incorporation O
of O
FA O
20:4;O O
into O
phospholipids, O
ω O
- O
and O
β O
-oxidation, O
and O
transformation O
of O
FA O
20:4;O O
via O
cyclooxygenase O
into O
prostaglandin O
analogs._, O

FA B-lipid
18:2 I-lipid
increased O
the O
NF-κB O
DNA-binding O
activity O
in O
nuclear O
extracts, O
as O
assessed O
by O
EMSA O
(2.2-fold O
at O
90 O
μmol/l O
linoleic O
acid; O
P O
< O
0.05) O

The O
structure O
of O
the O
fatty O
acyl O
side O
chains O
was O
identified O
by O
MS/MS: O
Peak#1: O
PC B-lipid
38:4, I-lipid
Peak#2: O
PC O
38:4, O
Peak#3 O
& O
4: O
PC O
38:4 O
(See O
text O
for O
more O
details). O

However, O
we O
excluded O
them O
from O
the O
statistical O
analyses O
as O
the O
relative O
SD O
for O
their O
corresponding O
internal O
standards O
(ChE O
(12:0) O
for O
ChE, O
DG B-lipid
24:0 I-lipid
for O
DG, O
and O
TG O
(16:0/16:0/16:0-13C3 O
for O
TG)) O
were O
>30%. O

Finally, O
an O
analysis O
of O
the O
postprandial O
behavior O
of O
candidate O
FIBs, O
in O
particular O
the O
dairy O
fatty O
acids O
pentadecanoic O
acid O
and O
FA B-lipid
17:0, I-lipid
revealed O
specific O
kinetic O
patterns O
of O
relevance O
to O
their O
detection O
in O
future O
validation O
studies. O

Finally, O
to O
ascertain O
that O
the O
two O
major O
markers O
identified, O
SM B-lipid
36:3;O2 I-lipid
and O
PC B-lipid
40:7, I-lipid
were O
genuine O
TFA O
markers O
in O
plasma O
we O
quantified O
them O
by O
a O
targeted O
lipidomics O
analysis O
of O
a O
subset O
of O
12 O
samples O
from O
each O
group O
using O
appropriate O
internal O
standards. O

The O
LOX O
products O
FA B-lipid
20:4;O I-lipid
and O
FA O
20:4;O O
are O
involved O
in O
chemotaxis O
of O
neutrophils O
[, O
–]. O

 O
40 O
μ O
L O
of O
each O
sample O
was O
added O
to O
160 O
μ O
L O
of O
water O
and O
480 O
μ O
L O
of O
extraction O
liquid O
(V_MTBE O
: O
V_methanol O
= O
5:1, O
containing O
10 O
μ O
L O
of O
160 O
μ O
g/mL O
PC B-lipid
33:1) I-lipid
and O
vortexed O
vigorously O
for O
60 O
s. O

Levels O
of O
l-proline, O
valine, O
l-leucine/isoleucine, O
hypoxanthine, O
glutamine, O
l-methionine, O
phenylpyruvic O
acid, O
several O
carnitine O
derivatives, O
and O
lysoPCs O
(C14:0, O
PC B-lipid
16:0, I-lipid
C15:0, O
C16:0, O
C17:1, O
C18:0, O
and O
C22:0) O
were O
significantly O
decreased. O

Among O
the O
differentially O
expressed O
metabolite, O
serum O
levels O
of O
LPC B-lipid
18:2, I-lipid
PhePhe, O
taurine, O
and O
L-threonine O
were O
negatively O
correlated, O
while O
levels O
of O
FA B-lipid
16:0;O I-lipid
were O
positively O
correlated O
with O
clinical O
activity O
scores O
in O
AOSD O
patients. O

ANN O
analysis O
showed O
that O
the O
most O
important O
predictors O
for O
the O
ADs O
were O
the O
following: O
Cis-11-eicosenoic O
(C20:1n9), O
lauric O
acid O
(C12:0), O
Erucic O
(C22:1n9), O
Cis-10 O
pentadecanoic O
acid O
(C15:1), O
stearic O
acid O
(C18:0), O
myristic O
acid O
(C14:0), O
FA B-lipid
17:0 I-lipid
(C17:0), O
palmitic O
acid O
(C16:0) O
in O
the O
order O
of O
importance. O

In O
addition, O
a O
decrease O
in O
the O
total O
level O
of O
LPI O
and O
marginally O
significant O
decreases O
in O
major O
PI O
species O
including O
PI B-lipid
38:4, I-lipid
36:2, O
36:3, O
34:2 O
were O
also O
observed O
in O
diabetic O
monkeys O
under O
fed O
conditions. O

We O
were O
able O
to O
corroborate O
the O
elevated O
PGE_2 O
and O
FA B-lipid
20:4;O I-lipid
CSF O
levels O
that O
were O
recently O
reported O
in O
MS O
patients O
as O
a O
quantitative O
CSF O
marker O
of O
neuroinflammation O
and O
oxidative O
stress. O

FA B-lipid
18:2 I-lipid
increased O
LPL O
and O
MCP-1 O
mRNA O
and O
protein, O
and O
this O
effect O
was O
prevented O
by O
pretreatment O
with O
2.5 O
μg/ml O
parthenolide, O
an O
NF-κB O
inhibitor O
(,) O
(A–D O
) O
(,). O

A O
net O
reclassification O
index O
(NRI) O
analysis O
demonstrated O
that O
the O
addition O
of O
SM B-lipid
34:1;O2 I-lipid
and O
SM B-lipid
36:1;O2 I-lipid
to O
the O
current O
clinical O
standard O
of O
HbA1c O
or O
HbA1c O
plus O
BMI O
provides O
moderately O
improved O
accuracy O
of O
the O
prediction O
of O
diabetes O
incidence O
for O
38%–40% O
of O
individuals. O

In O
muscle, O
Cer B-lipid
36:1;O2 I-lipid
was O
the O
only O
lipid O
higher O
in O
insulin O
resistance O
independent O
of O
overweight/obesity. O

This O
result O
is O
consistent O
with O
literature O
reports, O
where O
PE B-lipid
34:1, I-lipid
PE B-lipid
36:2, I-lipid
PE B-lipid
38:4, I-lipid
PC B-lipid
32:1, I-lipid
and O
PC B-lipid
36:2 I-lipid
have O
been O
identified O
to O
have O
significant O
changes O
in O
breast O
cancer O
cell O
lines O
or O
tissue O
samples. O

The O
15-lipooxygenase O
product O
FA B-lipid
20:4;O, I-lipid
a O
lipid O
signalling O
eicosanoid O
involved O
in O
inflammation O
and O
endothelial O
cell O
adhesion, O
was O
also O
identified O
as O
a O
potentially O
important O
metabolic O
signature O
of O
HCC, O
possessing O
a O
sensitivity O
of O
83.3 O
and O
a O
specificity O
of O
59.3 O
for O
HCC O
presence O
(AUC O
= O
0.705, O
P O
= O
0.0011). O

compares O
the O
nanoESI-MS O
spectra O
of O
PC B-lipid
34:1 I-lipid
(2 O
μM) O
in O
negative O
ion O
mode O
derived O
from O
solutions O
containing O
5 O
mM O
NH_4 O
HCO_3 O
and O
NH_4 O
COOH, O
respectively. O

The O
correlation O
analysis O
of O
LPC O
with O
PC O
species O
resulted O
in O
significant O
positive O
associations O
in O
most O
cases, O
except O
for O
LPC O
14:0 O
and O
PC B-lipid
38:6. I-lipid

13- O
hydroxyoctadecadienoic O
acid, O
and O
the O
lysophosphatidylcholines O
PC O
(20:0/0:0), O
PC O
(201/0:0), O
LPC B-lipid
22:5, I-lipid
and O
LPC B-lipid
17:0 I-lipid
were O
associated O
with O
the O
relapse-free O
status. O

HTG O
was O
defined O
according O
to O
the O
National O
ST B-lipid
27:1;O I-lipid
Education O
Program—Adult O
Treatment O
Panel O
III. O

The O
possible O
protective O
role O
of O
omega-3 O
fatty O
acids O
on O
type O
2 O
diabetes O
in O
Asians, O
particularly O
Chinese, O
was O
partly O
supported O
by O
our O
findings O
that O
increased O
omega-3 O
fatty O
acids, O
such O
as O
α O
-linolenic O
acid, O
FA B-lipid
20:5, I-lipid
and O
FA B-lipid
22:6, I-lipid
were O
observed O
only O
in O
prevalent O
type O
2 O
diabetes, O
which O
might O
elevate O
anti-inflammatory O
effects O
for O
self-stress O
protection. O

PC B-lipid
40:7 I-lipid
is O
annotated O
by O
the O
algorithm O
whereas O
SM B-lipid
36:3;O2 I-lipid
was O
characterised O
by O
MS/MS O
analysis O
using O
Li O
infusion. O

Using O
these O
metabolites O
we O
could O
reach O
a O
higher O
predictive O
value O
than O
using O
only O
FA B-lipid
22:6;O3. I-lipid

Importantly, O
no O
difference O
was O
observed O
in O
serum O
levels O
of O
PGE_2 O
and O
FA B-lipid
20:4;O, I-lipid
suggesting O
CNS-specific O
effects. O

Briefly, O
each O
100-ml O
serum O
sample O
was O
mixed O
with O
350 μl O
of O
methanol, O
and O
50 μl O
of O
FA B-lipid
17:0 I-lipid
(dissolved O
in O
methanol O
at O
a O
concentration O
of O
1 mg O
ml_−1 O
) O
was O
added O
as O
an O
internal O
standard. O

Only O
4 O
SPs, O
SM B-lipid
34:1;O2 I-lipid
and O
SM B-lipid
36:1;O2 I-lipid
and O
their O
metabolic O
precursors, O
Cer B-lipid
34:1;O2 I-lipid
and O
Cer B-lipid
36:1;O2, I-lipid
remained O
significant O
after O
adjustment O
for O
BMI, O
and O
when O
HbA1c O
was O
added O
to O
the O
model, O
only O
the O
2 O
SMs O
remained O
independently O
associated O
with O
T2DM O
incidence. O

used O
transition O
319 O
301 O
([M-H-H_2 O
O]-) O
as O
a O
surrogate O
of O
FA B-lipid
20:4;O. I-lipid

Lipid O
peroxidation O
results O
in O
the O
formation O
of O
lipid O
aldehydes O
– O
acrolein O
(AL), O
malondialdehyde O
(MDA) O
and O
FAL B-lipid
9:0;O I-lipid
(HNE) O
(Fig. O

The O
levels O
of O
PE B-lipid
32:1, I-lipid
PE B-lipid
34:3, I-lipid
PE B-lipid
34:2, I-lipid
PE B-lipid
34:0, I-lipid
PE B-lipid
35:2, I-lipid
PE B-lipid
35:1, I-lipid
PE O
35:1, O
PE B-lipid
36:5, I-lipid
PE B-lipid
36:1, I-lipid
PE B-lipid
38:5, I-lipid
PE B-lipid
38:3, I-lipid
PC B-lipid
33:1, I-lipid
PC B-lipid
36:6, I-lipid
and O
PC B-lipid
38:1 I-lipid
in O
early-stage O
NSCLC O
were O
significantly O
increased O
compared O
with O
HC O
(p<0.05). O

Presented O
are O
examples O
of O
lysophosphatidylcholines: O
LPC B-lipid
18:2 I-lipid

Among O
these O
metabolites, O
the O
high O
level O
of O
C8-ceramide, O
palmitoylcarnitine, O
hypoxanthine, O
linoleamide, O
palmitic O
amide, O
methionine, O
sphingosine O
and O
inosine, O
and O
the O
low O
level O
of O
isoleucine, O
valine, O
glutamine, O
LPC B-lipid
18:2, I-lipid
LPC B-lipid
20:3 I-lipid
and O
LPC B-lipid
22:5 I-lipid
were O
observed O
in O
HAPE O
subjects O
relative O
to O
healthy O
controls. O

Mediation O
analysis O
shows O
that O
LPC B-lipid
15:0 I-lipid
mediated O
the O
relationship O
between O
ascites O
and O
recurrence O
of O
EOC. O

The O
lipid O
profile O
of O
a O
grade O
III O
astrocytoma O
contains O
lipid O
species O
of O
all O
PS, O
PI O
and O
ST O
classes, O
while O
the O
grade O
III O
oligodendroglioma O
shows O
a O
distinct O
profile O
of O
lipid O
species O
with O
PS B-lipid
40:4 I-lipid
m/z O
838.3, O
and O
PI B-lipid
38:4 I-lipid
m/z O
885.5 O
present O
at O
much O
higher O
relative O
abundances O
than O
observed O
in O
the O
pure O
astrocytoma. O

We O
also O
used O
Mass O
Hunter O
Quantitative O
Analysis O
B.07.00 O
to O
quantify O
the O
FA B-lipid
20:4;O I-lipid
in O
which O
the O
deuterated O
internal O
standard O
FA O
20:4;O-d8 O
(Cayman O
Chemical) O
was O
used. O

_, O
Extracted O
ions O
from O
LC-OzID-IMS O
of O
human O
plasma O
showing O
(a) O
co-eluting O
PC B-lipid
36:1, I-lipid
SM B-lipid
40:2;O2 I-lipid
and O
SM B-lipid
38:1;O2, I-lipid
and O
(b) O
polyunsaturated O
PC B-lipid
32:2 I-lipid
co-eluting O
with O
SM B-lipid
34:2;O2. I-lipid

Both O
valine O
and O
isoleucine O
are O
considered O
glucogenic, O
being O
metabolized O
to O
CoA B-lipid
3:0 I-lipid
and O
acetyl-CoA, O
respectively. O

Plasma O
levels O
of O
metabolites O
in O
healthy O
subjects O
and O
in O
patients O
who O
underwent O
carotid O
endarterectomy O
(CE): O
(a) O
FA B-lipid
20:4;O; I-lipid
(b) O
Arachidonic O
acid; O
(c) O
FA O
20:4;O; O
(d) O
11(12)-DiHETE; O
(e) O
FA O
20:4;O; O
(f) O
14(15)-DiHETE. O

This O
ceramide O
would O
act O
as O
a O
precursor O
to O
the O
SM B-lipid
36:3;O2 I-lipid
formed O
by O
SM O
synthase O
(EC O
2.7.8.27). O

FA B-lipid
20:4;O I-lipid
activation O
of O
small-GTPase O
Ras O
is O
consistent O
with O
previous O
findings O
by O
others O
that O
FA O
20:4;O O
can O
act O
as O
a O
second O
messenger O
in O
the O
mitogenic O
actions O
of O
some O
growth O
factors O
and O
activate O
the O
ERK O
and O
PI3K-Akt O
cascades. O

These O
include O
palmitic O
acid, O
stearic O
acid, O
oleic O
acid, O
benzoic O
acid, O
FA B-lipid
4:0, I-lipid
cholesterol, O
glycine, O
3-heptanone, O
4-heptanone, O
FAL B-lipid
6:0, I-lipid
1-tetradecanol O
and O
naphthalene. O

We O
found O
that O
LPE B-lipid
22:5, I-lipid
SM B-lipid
36:3;O2, I-lipid
LPC B-lipid
16:0, I-lipid
LPC O
(15:1(9z)/0:0), O
and O
PC B-lipid
40:2 I-lipid
are O
significantly O
lower O
in O
NRP O
at O
t0, O
whereas O
the O
LPE O
level O
significantly O
increases O
in O
NRP O
during O
CRT. O

When O
the O
spectrum O
for O
12-oxo O
FA B-lipid
20:4;O2 I-lipid
and O
one O
of O
these O
unknowns O
was O
compared, O
it O
was O
observed O
that O
their O
patterns O
were O
highly O
similar O
thus O
indicating O
a O
common O
chemical O
structure O
(–). O

The O
amount O
of O
lipids O
synthesized O
downstream O
Fads1 O
such O
as O
arachidonic O
acid O
(C20:4n-6), O
FA B-lipid
20:5 I-lipid
(C20:5n-3) O
and O
FA B-lipid
22:6 I-lipid
(C22:6n-3) O
were O
dramatically O
decreased O
in O
livers O
of O
mice O
fed O
MCDD. O

As O
a O
result, O
three O
metabolites O
including O
inosine, O
AFMK O
and O
LPS B-lipid
O-18:0 I-lipid
were O
selected O
to O
establish O
a O
binary O
logistic O
regression O
model O
on O
the O
discovery O
set. O

TAG O
profiles O
in O
human O
and O
monkey O
plasma O
demonstrated O
that O
monkey O
plasma O
contained O
higher O
levels O
of O
TG B-lipid
52:5, I-lipid
52:4, O
56:8, O
56:7, O
56:6, O
58:10, O
58:9, O
58:8, O
58:7 O
and O
58:6. O

Seven O
VOCs, O
namely O
2-methylpentane-1,3-diol, O
1-(3,5-dimethylfuran-2-yl)ethanone, O
methyl O
benzoate, O
FA B-lipid
9:0, I-lipid
cyclohexanone, O
4-methylbenzaldehyde O
(Fig. O
), O
and O
4-methylheptan-2-one O
were O
significantly O
decreased O
in O
the O
extracellular O
medium O
of O
all O
PCa O
cell O
lines O
when O
compared O
with O
normal O
cell O
line O
(Table O
). O

Hepatic O
levels O
of O
(a) O
arachidonic O
acid O
(C20:4n-6), O
eicosapentanoic O
acid O
(C20:5n-3), O
and O
FA B-lipid
22:6 I-lipid
(C22:6n-3) O
in O
the O
patients O
studied O
(upper O
panel) O
and O
mouse O
models O
(lower O
panel). O

In O
this O
metabolomics O
study, O
univariate O
analysis O
showed O
that O
FA B-lipid
6:2, I-lipid
4-methylphenyl O
dodecanoate, O
glycerol O
tributanoate, O
methionyl-methionine O
and O
PG O
might O
be O
the O
prognostic O
factors O
for O
GC O
(Table O
). O

Hence, O
it O
seems O
interesting O
to O
publish O
our O
results O
on O
FA B-lipid
20:4;O I-lipid
as O
a O
possible O
metabolite O
related O
to O
this O
pathology. O

Measurements O
of O
lipids O
composed O
of O
two O
fatty O
acids O
are O
determined O
as O
the O
sum O
of O
the O
carbons O
and O
the O
double O
bonds O
across O
both O
fatty O
acids, O
e.g. O
PC B-lipid
36:4 I-lipid
based O
on O
previous O
methods O
(Weir O
et O
al. O
; O

Metabolites O
such O
as O
phosphoric O
acid, O
glycine O
and O
FA B-lipid
18:0 I-lipid
were O
unique O
to O
the O
disease O
survival O
model. O

In O
our O
study, O
FA B-lipid
20:4;O I-lipid
and O
FA O
20:4;O O
were O
significantly O
downregulated O
in O
DC O
vs. O
NHC, O
but O
experienced O
a O
rebound O
in O
expression O
in O
the O
HCC O
group, O
with O
both O
compounds O
exhibiting O
significant O
elevation O
in O
HCC O
vs. O
DC. O

Due O
to O
all O
these O
neuroprotective O
properties, O
decreased O
plasma O
levels O
of O
LPC B-lipid
16:0 I-lipid
could O
contribute O
to O
an O
early O
SR O
risk. O

However, O
PC B-lipid
32:0, I-lipid
and O
PC B-lipid
38:4 I-lipid
decreased O
in O
MF O
tissue O
compared O
to O
adjacent O
non-tumor O
tissue. O

We O
further, O
additionally, O
demonstrated O
that O
the O
mechanism O
of O
signaling O
of O
FA B-lipid
20:4;O I-lipid
in O
regulation O
of O
cell O
growth O
is O
via O
activation O
of O
the O
small-GTPase O
Ras O
in O
HRPTEC O
cells. O

The O
LPCAT1, O
which O
converts O
LPC O
into O
PCs, O
is O
overexpressed O
in O
several O
cancers O
and O
is O
associated O
with O
colon O
cancer O
growth O
(, O
) O
showed O
that O
LPCAT4 O
was O
overexpressed O
in O
CRC O
and O
contributes O
to O
PC B-lipid
32:1 I-lipid
accumulation O
via O
the O
enhanced O
re-acylation O
of O
LPC. O

All O
the O
metabolites O
measured O
in O
this O
study O
were O
detected O
in O
all O
608 O
serum O
samples O
except O
LPI B-lipid
22:6, I-lipid
which O
was O
detected O
in O
92.4% O
of O
all O
samples. O

The O
metabolome O
revealed O
marked O
elevation O
of O
metabolites O
sensitive O
to O
asphyxia, O
including O
succinic O
acid, O
glutamic O
acid, O
malate, O
and O
FA B-lipid
4:0. I-lipid

The O
levels O
of O
alchornoic O
acid, O
PI O
(13 : 0/22 : 1), O
FA B-lipid
24:2;O, I-lipid
FA B-lipid
22:1;O, I-lipid
and O
anhydrorhodovibrin O
were O
decreased O
in O
the O
newly O
diagnosed O
T2DM O
group O
with O
fold O
changes O
of O
9.74, O
5.97, O
4.07, O
3.51, O
and O
3.27, O
respectively. O

On O
the O
other O
hand O
PCs O
containing O
32 O
carbons O
(32:2 O
and O
32:1) O
and O
SM B-lipid
38:3;O2 I-lipid
significantly O
increased O
their O
levels O
during O
radiotherapy O
(cluster O
#3) O
(see O
). O

Significant O
correlations O
between O
lipid O
levels O
and O
cortical O
gray O
matter O
density. O
LPC B-lipid
18:0 I-lipid
level O
is O
positively O
correlated O
with O
gray O
matter O
density O
mainly O
in O
right O
precentral O
gyrus, O
anterior O
cingulate O
areas, O
and O
medial O
parietal O
and O
occipital O
surfaces. O

FA B-lipid
20:4;O I-lipid
producing O
CYP450 O
isoform O
specific O
primer O
sequences O
were O
as O
follows: O
CYP4A11-F O
(ATGAAGTGTGCCTTCAGCCA), O
CYP4A11-R O
(AAG O
GCATTCC O
TCACACGGG), O
CYP4A22-F O
(AATGGGAAGAGCTCCTTGGC), O
CYP4A22-R O
(AAGGCATTCCTCATACAGC), O
CYP4F2-F O
(AAGCA O
CCCAGAATACCAGGA), O
CYP4F2-R O
(TCATGCACA O
TGGTCAG O
GAAG), O
CYP4F3-F(CTGTCGGCAGGAGGTACAAG), O
CYP4F3-R O
(CCTCAGGCTCTCCTTAATGC). O

Eight O
PS O
lipids O
were O
identified O
and O
were O
statistically O
(P O
value O
<0.05) O
higher O
in O
fatalities O
in O
our O
study, O
with O
the O
exception O
of O
PS B-lipid
38:4 I-lipid
( O
and O
SI O
Appendix O
, O
Table O
S2). O

All O
these O
results O
might O
indicate O
that O
low O
serum O
levels O
of O
FA B-lipid
6:2, I-lipid
4-methylphenyl O
dodecanoate O
and O
glycerol O
tributanoate O
may O
be O
independent O
prognostic O
factors O
of O
GC. O

Lastly, O
we O
also O
have O
to O
acknowledge O
that O
isoprostane O
is O
an O
indicator O
of O
systemic O
marker O
of O
oxidative O
stress O
and O
may O
not O
reflect O
localized O
lipid O
peroxidation O
such O
as O
FAL B-lipid
9:0;O I-lipid
and O
malondialdehyde, O
commonly O
found O
in O
sperm. O

Specifically, O
centenarians O
exhibit O
lower O
concentration O
of O
FA B-lipid
20:3;O2 I-lipid
(FA O
20:3;O2), O
FA B-lipid
18:2;O I-lipid
(9-HODE), O
and O
FA B-lipid
18:3;O I-lipid
(9-oxo-HODE), O
and O
increased O
concentrations O
of O
FA B-lipid
20:4;O I-lipid
(15-HETE), O
and O
leukotriene O
E4 O
(LTE4). O

PNT2, O
DU145 O
vs O
PNT2), O
5-methylheptan-2-one O
(PC3 O
vs O
PNT2, O
DU145 O
vs O
PNT2 O
and O
LNCaP O
vs O
PNT2), O
phenylethanol O
(22RV1 O
vs O
PNT2, O
PC3 O
vs O
PNT2, O
DU145 O
vs O
PNT2), O
FA B-lipid
10:0 I-lipid
(22RV1 O
vs O
PNT2 O
and O
LNCaP O
vs O
PNT2), O
benzyl O
acetate O
(22RV1 O
vs O
PNT2 O
and O
LNCaP O
vs O
PNT2), O
5-methyl-2-propan-2-ylcyclohexan-1-ol O
(PC3 O
vs O
PNT2 O
and O
LNCaP O
vs O
PNT2), O
1-ethoxypentane O
(DU145 O
vs O
PNT2 O
and O
LNCaP O
vs O
PNT2), O
methyl O
nonanoate O
(22RV1 O
vs O
PNT2), O
2-ethoxy-2-methylbutane O
(PC3 O
vs O
PNT2), O
FA B-lipid
6:0 I-lipid
(PC3 O
vs O
PNT2), O
phenylmethanol O
(PC3 O
vs O
PNT2), O
2,4-dimethylheptan-1-ol O
(PC3 O
vs O
. O
PNT2), O
benzoic O
acid O
(PC3 O
vs O
PNT2), O
6-pentyloxan-2-one O
(PC3 O
vs O
PNT2) O
(Table O
). O

Alterations O
in O
levels O
of O
CYP O
enzymes, O
FA B-lipid
20:4;O I-lipid
or O
EETs O
contribute O
to O
endothelial O
dysfunction O
and O
cardiovascular O
diseases O
such O
as O
ischemic O
injury, O
hypertension O
and O
atherosclerosis O
[,]. O

At O
1 month O
the O
LPC B-lipid
20:2, I-lipid
LPC B-lipid
22:5 I-lipid
and O
SM B-lipid
32:0;O2 I-lipid
species O
were O
significantly O
negatively O
associated O
to O
C-peptide O
levels O
after O
correction O
for O
multiple O
testing O
and O
at O
1 month, O
cholesteryl O
esters O
were O
associated O
to O
lower O
C-peptide O
levels O
at O
6 months O
(Table ). O

Metabolites O
in O
GSH O
biosynthesis O
and O
methionine O
metabolism O
e.g., O
cysteine, O
FA B-lipid
4:0;O, I-lipid
and O
oxoproline, O
were O
significantly O
different O
in O
WD. O

Cer B-lipid
22:0;O2 I-lipid

(E) O
[M + Na]_+ O
of O
PI B-lipid
32:2. I-lipid

Highest O
mean O
concentrations O
were O
detected O
for O
polyunsaturated O
species O
with O
more O
than O
two O
double O
bonds: O
DG B-lipid
36:3, I-lipid
DG B-lipid
36:4, I-lipid
TG B-lipid
54:3, I-lipid
TG B-lipid
54:4, I-lipid
and O
TG B-lipid
54:5. I-lipid

Additional O
CID O
spectra O
performed O
in O
the O
negative O
ionization O
mode O
enabled O
to O
determine O
the O
presence O
of O
the O
fatty O
acids O
FA O
16:1 O
(m/z O
253.2172) O
(b) O
and O
FA B-lipid
16:0 I-lipid
(m/z O
255.2327) O
(c), O
corresponding O
to O
two O
distinct O
PC O
species, O
namely O
alkyl–acyl-PC O
32e:1 O
and O
alkenyl–acyl-PC32p:0 O

As O
shown O
in O
, O
the O
responses O
of O
interfering O
peaks O
from O
blank O
were O
less O
than O
1% O
of O
that O
of O
Cer B-lipid
22:0;O2 I-lipid
and O
Cer B-lipid
24:0;O2 I-lipid
in O
LLOQ O
and O
less O
than O
1% O
of O
that O
of O
internal O
standards. O

For O
semi-quantification O
of O
other O
metabolites, O
100 O
μl O
of O
serum O
was O
mixed O
with O
two O
internal O
standard O
solutions O
(10 O
μl O
of O
l-2-chlorophenylalanine O
in O
water, O
0.3 O
mg/ml; O
10 O
μl O
of O
FA B-lipid
17:0 I-lipid
in O
methanol, O
1 O
mg/ml) O
and O
300 O
μl O
of O
methanol/chloroform O
(v/v O
= O
3/1). O

Adjusted O
OR O
(95% O
CI) O
of O
MI, O
IS, O
and O
ICH O
for O
Mean O
Particle O
Diameter, O
ST B-lipid
27:1;O, I-lipid
Triglycerides, O
and O
Apolipoproteins O
as O
Measured O
by O
Nuclear O
Magnetic O
Resonance O
Spectroscopy O
Estimates O
are O
ORs O
per O
1-SD O
higher O
metabolic O
marker. O

Their O
mean O
± O
SD O
concentrations O
in O
HCC O
plasma O
versus O
AML, O
LC, O
and O
HV O
plasma O
is O
given O
in O
and O
for O
lignoceric O
acid O
(FA O
24:0) I-lipid
and O
nervonic O
acid O
(FA O
24:1) I-lipid
are O
shown O
in O
. O

N(alpha)-t-Butoxycarbonyl-L-leucine; O
COM530: O
PA B-lipid
38:8; I-lipid
COM548: O
LPE B-lipid
O-16:1; I-lipid
COM732: O
Val O
Arg O
Phe. O

Also O
in O
that O
report, O
the O
authors O
demonstrated O
that O
the O
extractive O
response O
of O
the O
sorbent O
was O
greater O
when O
larger O
sample O
headspace O
volumes O
were O
used, O
at O
least O
for O
the O
model O
metabolites O
isoprene, O
pentane, O
toluene O
and O
FAL B-lipid
5:0. I-lipid

